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ABSTRACT: Treatment of homoallylic N-tosyl amines or allylic N-tosyl hydroxylamines with 1.5 equiv 
of a malonoyl peroxide provides a stereoselective method to access functionalized pyrrolidines and isox-
azolidines. This metal free alkene oxyamination proceeds in 55–85% yield and up to 13:1 trans-selectiv-
ity. In addition, the relative stereochemistry of the oxygen and nitrogen substituents can be inverted 
through an oxidation/reduction sequence. Mechanistic investigations show a higher reactivity for hy-
droxyl nucleophiles over sulfonamide nucleophiles revealing a preference for dioxygenation over oxyam-
ination. 
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The vicinal functionalization of alkenes is one of the most studied transformations in organic synthesis. 
This is particularly the case for the introduction of new carbon—heteroatom bonds generating up to two 
new stereogenic centers. For example, exquisite success has been achieved in dihydroxylation processes 
whereby the majority of alkene building blocks can be transformed stereo- and enantioselectively into the 
corresponding syn- or anti-diol using commercial reagents under mild and efficient conditions.1–3 
 Whilst significant efforts have been devoted to the di-oxygenation of alkenes, methods for oxy-
amination are substantially less developed, despite the accordant potential for the products in pharmaceu-
tical and agrochemical research.4 The majority of methods developed for oxyamination involve the use 
of transition metal catalysts, including osmium,5,6 rhodium,7 palladium,8 copper9 and iron.10 Metal free 
methods have also been described and include both iodine(0)11 and iodine(III)12 species as the reagent. 
Despite the extensive inroads made in the development of effective methods for the oxyamination of 
alkenes using these processes significant opportunities still exist in the area with regards to regio- and 
stereoselectivity along with substrate scope and the use of more environmentally benign catalysts, rea-
gents, and reaction conditions. 
 We have recently shown that malonoyl peroxide 1 and its derivatives are versatile reagents for 
both the syn-13 and anti-dioxygenation14,15 of alkenes. In the preparation of oxygen heterocycles transfor-
mations proceed through the reaction of the substrate alkene 2 with the malonoyl peroxide to give a diox-
onium intermediate 316 which can react stereoselectively in an intramolecular fashion with either an alco-
hol or a carboxylic acid to give the corresponding tetrahydrofuran or -lactone respectively (Scheme 1). 
Encouraged by the success of this work we sought to discover if the overall strategy could be applied to 
the preparation of nitrogen containing heterocycles through the reaction of alkenes tethered directly to a 
nitrogen nucleophile (e.g. 5). Within this paper we describe the development of a simple and effective 
intramolecular oxyamination procedure to deliver 2-hydroxypyrrolidine derivatives 7 in a stereoselective 
manner. 
Scheme 1. Intramolecular Oxidative Cyclizations 
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 Our investigation began with the reaction of a homoallylic amine 8a (R = Ts) with malonoyl per-
oxide 1 (Table 1). Chlorinated solvents, which had proved effective in both the syn- and anti-dioxygena-
tion of alkenes,13,14 led to slow consumption of starting materials with no clear indication of the desired 
pyrrolidine product 9a (R = Ts) (entries 1 and 2). However, reaction of 8a with 1.5 equiv of malonoyl 
peroxide 1 at room temperature for 5 h in hexafluoroisopropanol (HFIP) followed by hydrolysis of the 
product led to the desired trans-3-hydroxypyrrolidine 9a in an excellent 69% isolated yield and a 1:9 
cis:trans selectivity (entry 3). Drying the HFIP solvent over 3 Å molecular sieves for 24 h prior to use 
provided the product in a similar yield and improved selectivity (entry 4; 71%; 1:13 cis:trans). Interest-
ingly, despite extensive efforts to induce similar reactivity with alternative amide 8b (entry 5), carbamate 
8c and 8d (entries 6 and 7) and sulfonamide 8e (entry 8) substituents on the nitrogen nucleophile, similar 
reactivity patterns could not be observed upon complete consumption of starting material. In each of these 
transformations numerous products were present in the 1H NMR of the crude reaction mixture with no 
clear evidence for the formation of the target pyrrolidines. This suggests that both the electronics and 
sterics of the nitrogen nucleophile are crucial to observing the desired reactivity and that N-tosylsulfona-
mides provide the environment required to promote reactivity. 
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Table 1. Influence of Nitrogen Substituent 
 
 Confirmation of the structure of the cyclized pyrrolidine 10, prior to hydrolysis, came from single 
crystal X-ray crystallography (Figure 1). This structure clearly shows the trans-relationship between the 
phenyl group from the alkene substrate and the ester group from the malonoyl peroxide reagent. Overall, 
this provides a convenient, mild and effective method for the anti-oxyamination of alkenes. 
 
Figure 1. Single-crystal X-ray structure of pyrrolidine 10. 
 Having established an efficient method for the oxyamination of 8a (R = Ts) we went on to examine 
some of the scope of the process (Table 2). Substitution on all positions of the aromatic ring was tolerated 
with p- (entry 2; 66%; 1:7 cis:trans), m- (entry 3; 71%; 1:6 cis:trans) and o-tolyl (entry 4; 72%) substrates 
effectively undergoing the intramolecular oxyamination process. Chloride substitution was also well tol-
erated (entries 6 and 7), providing the products in up to 67% isolated yield which could readily be diver-
sified. Alternative substitution on the aromatic ring that was also investigated included a p-phenyl sub-
stituent (entry 5; 72%; 1:9 cis:trans) and an acetal group (entry 8; 55%; 1:9 cis:trans). 
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Table 2. Substrate Scope for Oxyamination Procedure 
 
 
 A limitation was encountered with the introduction of the strongly electron withdrawing trifluoro-
methyl substituent which was significantly slower than the other substrates examined. Conducting the 
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reaction at a higher temperature of 50 °C for 20 h gave the product 20 in just 19% isolated yield (entry 9). 
Whilst 1H NMR spectroscopy supported the structure of 20 it was not possible to determine the stereose-
lectivity due to overlapping signals. Introduction of further substitution on the alkene substrate was also 
possible with the diphenyl-substituted pyrrolidine 21 being isolated in an excellent 82% yield (entry 10), 
providing the most efficient pyrrolidine synthesis examined within this study. Use of a Z-alkene substrate 
gave the cis-pyrrolidine product 22 as a 5:1 mixture of cis- and trans-isomers (entry 11). 
 Mechanistically we believe that the reaction is proceeding as outlined in Figure 2. Nucleophilic 
attack of the substituted alkene 23 on the peroxide 1 leads to 24 which cyclizes intramolecularly to give 
the dioxonium species 25 as defined previously for alkene dihydroxylation.16 Subsequent cyclization of 
the nitrogen nucleophile forms the pyrrolidine ring 27 with a trans-relationship of the newly formed C—
O and C—N bonds. This mechanistic pathway is consistent with previous investigations into the reactivity 
of malonoyl peroxide 1 and accounts for the stereoselectivities observed within the process. 
 
Figure 2. Proposed mechanistic pathway for the intramolecular oxyamination procedure. 
 In order to understand the mechanism of this transformation further we prepared the probe mole-
cule 28, to ascertain if differences in nucleophilicity between heteroatoms could influence the outcome of 
the cyclization (Scheme 2). Compound 28 is a tetra-substituted alkene which contains both an alcohol and 
a sulfonamide nucleophile. Reaction of 28 under standard cyclization conditions followed by esterifica-
tion of the crude product gave the tetrahydrofuran 29 (46%). The pyrrolidine 30 was not detected by 1H 
NMR spectroscopy on the crude reaction mixture. This shows that on formation of a dioxonium ion in-
termediate 32 the more nucleophilic pendant heteroatom reacts selectively through carbon atom A. In 
addition, we also isolated a small amount of the bicyclic compound 31 (7%) which results from direct 
cyclization of the oxygen heteroatom on carbon atom B of the dioxonium intermediate 32. We believe 
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this product is formed due to the increased steric encumbrance of carbon atom A, reducing the reactivity 
of this center. 
Scheme 2. Probe to Understand Reaction Mechanism 
 
 To expand the scope of the transformation to alternative nitrogen containing heterocycles we pre-
pared the hydroxylamine derivatives 33 and 35 and reacted each with 1.5 equiv 1 (HFIP, 40 °C, 18 h) 
(Scheme 3). The elevated temperature and extended reaction times necessary to bring about reaction sug-
gest a reduced nucleophilicity of the nitrogen heteroatom within these substrates. After treatment of the 
crude reaction mixture with TMSCHN2 the isoxazolidines 34 (80%; 1:10 cis:trans) and 36 (85%; 1:7 
cis:trans) were isolated after purification by column chromatography. This provides an efficient and 
highly stereoselective method for the preparation of the 4-hydroxyisoxazolidine framework from readily 
accessible alkene substrates. 
Scheme 3. Preparation of Isoxazolidines 
 
 The structure of the isoxazolidine product 37, prior to esterification, was confirmed by single crys-
tal X-ray crystallographic analysis (Figure 3). In contrast to the structure of the pyrrolidine analogue 10 
the nitrogen atom adopts a tetrahedral geometry in this structure, with the isoxazolidine ring having a 
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more puckered conformation. The apparent reduced nucleophilicity of the hydroxylamine derivatives 33 and 35 
was surprising. Whilst we are unable to unequivocally explain this observation at present, the different structures 
of compounds 10 and 37 suggest that the conformation of the substrates may affect reactivity. 
 
Figure 3. Single crystal X-ray structure of isoxazolidine 37. 
 Reaction of the 3-hydroxypyrrolidine 9a with IBX (3 equiv) in acetonitrile gave the pyrrolidinone 
38 in 85% isolated yield (Scheme 4). Reduction of this ketone with DIBAL-H in THF at rt for 3 h gave 
the cis-substituted product 22 (6:1 cis:trans; 78%). This sequence provides an alternative access to the 
diasteremeric pyrrolidine product 22 without independent preparation of the Z-alkene substrate enhancing 
the overall use of the process described and the diversity of structures accessed using this methodology. 
Scheme 4. Inverting Relative Stereochemistry of Pyrrolidine Ring 
 
 In summary, we have described a simple and effective method for the intramolecular oxyamina-
tion of alkenes. Through optimization of the nitrogen substituent we have shown that the oxyamination 
procedure can be induced at room temperature by treatment of an alkene substrate with 1.5 equiv of 
malonoyl peroxide 1 in HFIP. The product can be isolated in good yield and up to 13:1 trans:cis ratio. The 
related isoxazolidines can also be prepared from the appropriate hydroxylamine substrate. In addition, the 
relative stereochemistry of the two newly formed carbon—heteroatom bonds can be changed by prepara-
tion of the Z-alkene substrate or through a simple oxidation-reduction sequence, further expanding the 
scope of this useful transformation. A mechanistic probe showed there is a preference for reaction of the 
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dioxonium intermediate with an alcohol over a sulfonamide nucleophile revealing a preference for diox-
ygenation over oxyamination. Current efforts are focused on developing an intermolecular variant of this 
procedure and we will report on our findings in the near future. 
Experimental Section 
Synthesis of malonoyl peroxide (1).15 Methane sulfonic acid (30 mL) was placed in a round bottomed flask 
equipped with a large magnetic stirrer bar and immersed in a bath of water at 22 °C. Urea hydrogen 
peroxide (9.8 g, 104.0 mmol) was added in a single portion and stirred for 30 seconds. Cyclopropane-1,1-
dicarboxylic acid (5.0 g, 38.5 mmol) was added in a single portion and the reaction stirred vigorously for 
18 h. The reaction mixture was poured into a mixture of ice (80 g) and ethyl acetate (100 mL) and the 
layers separated. The aqueous layer was extracted with ethyl acetate (2 × 100 mL) and the combined 
organics were washed with NaHCO3 (2 × 50 mL), brine (20 mL) and dried over MgSO4. Removal of the 
solvent under reduced pressure gave the desired peroxide 1 (3.5 g, 27.3 mmol, 71%). m.p. 90 °C; IR 
(ATR)/cm–1: 1827, 1798, 1358; 1H NMR (500 MHz, CDCl3) δ 2.10 (s, 4H); 13C NMR (126 MHz, CDCl3) 
δ 172.3, 23.7, 19.9. 
Synthesis of 2-(But-3-en-1-yl)isoindoline-1,3-dione.17 A dry three-neck flask was charged with potassium 
phthalimide (3.6 g, 19.2 mmol) in DMF (12 mL). 4-Bromobut-1-ene (1.5 mL, 14.8 mmol) was added and 
the mixture was stirred at reflux for 5 h. The mixture was allowed to cool to room temperature, poured 
onto ice and extracted with CH2Cl2 (3 × 50 mL). The combined organics were washed with 0.2 M KOH 
(50 mL), H2O (50 mL), dried over MgSO4, filtered and the solvent was removed by rotary evaporation to 
afford the title compound (2.8 g, 13.8 mmol, 93%) as a brown solid which was used without further 
purification. m.p. 49–51 °C, Lit18 [52–53 °C]; IR (ATR)/cm–1: 3075, 2974, 2939, 1772, 1705; 1H NMR 
(500 MHz, CDCl3) δ 7.85–7.81 (m, 2H), 7.72–7.68 (m, 2H), 5.79 (ddt, J = 17.1, 10.2, 6.9 Hz, 1H), 5.06 
(dd, J = 17.1, 1.5 Hz, 1H), 5.01 (d, J = 10.2 Hz, 1H), 3.76 (t, J = 7.1 Hz, 2H), 2.47–2.42 (m, 2H); 13C 
NMR (126 MHz, CDCl3) δ 168.5, 134.6, 134.0, 132.3, 123.3, 117.7, 37.5, 33.0; LRMS (ES + APCI) m/z: 
202.1 [M+H]+. 
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General Procedure 1: Heck Coupling.19 A dry three-neck flask fitted with a condenser was charged with 
aryl iodide (1.1 equiv) and Et3N (2.0 equiv) in MeCN (0.05 M). 2-(But-3-en-1-yl)isoindoline-1,3-dione 
(1.0 equiv) was added followed by P(o-tol)3 (10 mol%) and Pd(OAc)2 (5 mol%). The mixture was stirred 
at reflux until completion by TLC. The solution was allowed to cool to room temperature, passed through 
a plug of Celite® and the solvent was removed in vacuo. The crude residue was dissolved in EtOAc (100 
mL) and washed with 2 M HCl (× 2), H2O (× 2), dried over MgSO4, filtered and the solvent was removed 
by rotary evaporation. Purification by silica gel flash column chromatography with hexane:EtOAc mix-
tures afforded the target compounds. 
(E)-2-(4-Phenylbut-3-en-1-yl)isoindoline-1,3-dione.20 Phenyl iodide (1.7 mL, 14.8 mmol) and Et3N (3.7 
mL, 26.8 mmol) were dissolved in MeCN (270 mL) followed by addition of 2-(but-3-en-1-yl)isoindoline-
1,3-dione (2.7 g, 13.4 mmol), P(o-tol)3 (407 mg, 1.3 mmol) and Pd(OAc)2 (150 mg, 0.7 mmol) according 
to General Procedure 1 and the resulting mixture was heated at reflux for 16 h. Purification by silica gel 
flash column chromatography (hexane:EtOAc 9:1) afforded the title compound (2.2 g, 7.9 mmol, 60%) 
as a white solid. m.p. 138–139 °C, Lit20 [133.5–135.5 °C]; IR (ATR)/cm–1: 3054, 3025, 2935, 1695; 1H 
NMR (500 MHz, CDCl3) δ 7.84–7.82 (m, 2H), 7.70–7.69 (m, 2H), 7.30–7.27 (m, 4H), 7.20–7.18 (m, 1H), 
6.43 (d, J = 15.8 Hz, 1H), 6.18 (dt, J = 15.8, 7.1 Hz, 1H), 3.85 (t, J = 7.1 Hz, 2H), 2.63–2.59 (m, 2H); 
13C NMR (126 MHz, CDCl3) δ 168.3, 137.3, 133.9, 132.6, 132.1, 128.5, 127.2, 126.2, 126.1, 123.2, 37.6, 32.2; 
LRMS (ES + APCI) m/z: 278.0 [M+H]+. 
(E)-2-(4-p-Tolyl)but-3-en-1-yl)isoindoline-1,3-dione.21 4-Iodotoluene (600 mg, 2.7 mmol) and Et3N (700 
μL, 5.0 mmol) were dissolved in MeCN (50 mL) followed by addition of 2-(but-3-en-1-yl)isoindoline-
1,3-dione (500 mg, 2.5 mmol), P(o-tol)3 (75 mg, 0.3 mmol) and Pd(OAc)2 (28 mg, 0.1 mmol) according 
to General Procedure 1 and the resulting mixture was heated at reflux for 24 h. Purification by silica gel 
flash column chromatography (hexane:EtOAc 9:1) afforded the title compound (432 mg, 1.5 mmol, 60%) 
as a white solid. m.p. 121–122 °C; IR (ATR)/cm–1: 3023, 2922, 2854, 1708; 1H NMR (500 MHz, CDCl3) 
δ 7.84–7.81 (m, 2H), 7.71–7.68 (m, 2H), 7.19 (d, J = 8.0 Hz, 2H), 7.08 (d, J = 8.0 Hz, 2H), 6.40 (d, J = 
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15.9 Hz, 1H), 6.12 (dt, J = 15.9, 7.2 Hz, 1H), 3.83 (t, J = 7.2 Hz, 2H), 2.62–2.57 (m, 2H), 2.31 (s, 3H); 
13C NMR (126 MHz, CDCl3) δ 168.5, 137.1, 134.6, 134.0, 132.6, 132.3, 129.3, 126.2, 125.2, 123.4, 37.8, 
32.4, 21.3; LRMS (ES + APCI) m/z: 292.0 [M+H]+. 
(E)-2-(4-m-Tolyl)but-3-en-1-yl)isoindoline-1,3-dione.21 3-Iodotoluene (350 μL, 2.7 mmol) and Et3N (700 
μL, 5.0 mmol) were dissolved in MeCN (50 mL) followed by addition of 2-(but-3-en-1-yl)isoindoline-
1,3-dione (500 mg, 2.5 mmol), P(o-tol)3 (75 mg, 0.3 mmol) and Pd(OAc)2 (28 mg, 0.1 mmol) according 
to General Procedure 1 and the resulting mixture was heated at reflux for 20 h. Purification by silica gel 
flash column chromatography (hexane:EtOAc 9:1) afforded the title compound (528 mg, 1.8 mmol, 73%) 
as a colourless oil. IR (ATR)/cm–1: 3055, 2940, 2857, 1712; 1H NMR (500 MHz, CDCl3) δ 7.84–7.82 (m, 
2H), 7.70–7.68 (m, 2H), 7.16 (t, J = 7.4 Hz, 1H), 7.11 (s, 1H), 7.11–7.09 (m, 1H), 7.01 (d, J = 7.4 Hz, 
1H), 6.40 (d, J = 15.8 Hz, 1H), 6.16 (dt, J = 15.8, 7.1 Hz, 1H), 3.84 (t, J = 7.1 Hz, 2H), 2.63–2.58 (m, 
2H), 2.31 (s, 3H); 13C NMR (126 MHz, CDCl3) δ 168.5, 138.1, 137.3, 134.0, 132.8, 132.3, 128.5, 128.2, 
127.0, 126.0, 123.43, 123.37, 37.8, 32.4, 21.5; LRMS (ES + APCI) m/z: 292.0 [M+H]+. 
(E)-2-(4-o-Tolyl)but-3-en-1-yl)isoindoline-1,3-dione.21 2-Iodotoluene (350 μL, 2.7 mmol) and Et3N (700 
μL, 5.0 mmol) were dissolved in MeCN (50 mL) followed by addition of 2-(but-3-en-1-yl)isoindoline-
1,3-dione (500 mg, 2.5 mmol), P(o-tol)3 (75 mg, 0.3 mmol) and Pd(OAc)2 (28 mg, 0.1 mmol) according 
to General Procedure 1 and the resulting mixture was heated at reflux for 16 h. Purification by silica gel 
flash column chromatography (hexane:EtOAc 9:1) afforded the title compound (300 mg, 1.0 mmol, 42%) 
as a white solid. m.p. 132–134 °C; IR (ATR)/cm–1: 3056, 3017, 2939, 2855, 1706; 1H NMR (500 MHz, 
CDCl3) δ 7.84–7.83 (m, 2H), 7.71–7.69 (m, 2H), 7.35 (d, J = 6.9 Hz, 1H), 7.14–7.06 (m, 3H), 6.59 (d, J 
= 15.6 Hz, 1H), 6.12 (dt, J = 15.6, 7.5 Hz, 1H), 3.86 (t, J = 7.0 Hz, 2H), 2.66–2.61 (m, 2H), 2.20 (s, 3H); 
13C NMR (126 MHz, CDCl3) δ 168.5, 136.6, 135.2, 134.1, 132.3, 130.8, 130.2, 127.7, 127.3, 126.2, 126.0, 
123.4, 37.8, 32.6, 19.8; LRMS (ES + APCI) m/z: 292.0 [M+H]+. 
(E)-2-(4-(4-Chlorophenyl)but-3-en-1-yl)isoindoline-1,3-dione.22 1-Chloro-4-iodobenzene (1.3 g, 5.5 
mmol) and Et3N (1.4 mL, 10.0 mmol) were dissolved in MeCN (100 mL) followed by addition of 2-(but-
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3-en-1-yl)isoindoline-1,3-dione (1.0 g, 4.97 mmol), P(o-tol)3 (151 mg, 0.5 mmol) and Pd(OAc)2 (56 mg, 
0.3 mmol) according to General Procedure 1 and the resulting mixture was heated at reflux for 42 h. 
Purification by silica gel flash column chromatography (hexane:EtOAc 9:1) afforded the title compound 
(1.1 g, 3.4 mmol, 68%) as a white solid. m.p. 130–131 °C, Lit22 [130.5–132.0 °C]; IR (ATR)/cm–1: 3058, 
3025, 3002, 2939, 1699; 1H NMR (500 MHz, CDCl3) δ 7.84–7.82 (m, 2H), 7.71–7.69 (m, 2H), 7.23 (d, J 
= 8.8 Hz, 2H), 7.21 (d, J = 8.8 Hz, 2H), 6.37 (d, J = 15.8 Hz, 1H), 6.15 (dt, J = 15.8, 7.1 Hz, 1H), 3.84 
(t, J = 7.1 Hz, 2H), 2.62–2.58 (m, 2H); 13C NMR (126 MHz, CDCl3) δ 168.5, 135.9, 134.1, 133.0, 132.2, 
131.5, 128.8, 127.5, 127.1, 123.4, 37.6, 32.4; LRMS (ES + APCI) m/z: 328.9 [M+NH4]+. 
(E)-2-(4-(3-Chlorophenyl)but-3-en-1-yl)isoindoline-1,3-dione.23 1-Chloro-3-iodobenzene (2.0 g, 8.4 
mmol) and Et3N (2.1 mL, 15.2 mmol) were dissolved in MeCN (150 mL) followed by addition of 2-(but-
3-en-1-yl)isoindoline-1,3-dione (1.53 g, 7.6 mmol), P(o-tol)3 (232 mg, 0.8 mmol) and Pd(OAc)2 (86 mg, 
0.4 mmol) according to General Procedure 1 and the resulting mixture was heated at reflux for 48 h. 
Purification by silica gel flash column chromatography (hexane:EtOAc 9:1) afforded the title compound 
(1.8 g, 5.8 mmol, 76%) as a brown solid. m.p. 106–108 °C; IR (ATR)/cm–1: 3056, 3025, 2935, 2854, 
1708; 1H NMR (500 MHz, CDCl3) δ 7.85–7.81 (m, 2H), 7.72–7.68 (m, 2H), 7.26 (s, 1H), 7.21–7.14 (m, 
3H), 6.36 (d, J = 15.8 Hz, 1H), 6.19 (dt, J = 15.8, 7.1 Hz, 1H), 3.84 (t, J = 7.1 Hz, 2H), 2.63–2.59 (m, 
2H); 13C NMR (126 MHz, CDCl3) δ 168.5, 139.2, 134.6, 134.1, 132.2, 131.5, 129.8, 128.0, 127.3, 126.3, 
124.5, 123.4, 37.6, 32.2; LRMS (ES + APCI) m/z: 329.0 [M+NH4]+. 
(E)-2-(4-([1,1'-Biphenyl]-4-yl)but-3-en-1-yl)isoindoline-1,3-dione. 4-Iodo-1,1'-biphenyl (1.7 g, 6.1 
mmol) and Et3N (1.5 mL, 11.0 mmol) were dissolved in MeCN (110 mL) followed by addition of 2-(but-
3-en-1-yl)isoindoline-1,3-dione (1.1 g, 5.5 mmol), P(o-tol)3 (168 mg, 0.6 mmol) and Pd(OAc)2 (62 mg, 
0.3 mmol) according to General Procedure 1 and the resulting mixture was heated at reflux for 72 h. 
Purification by silica gel flash column chromatography (hexane:EtOAc 8:2) afforded the title compound 
(0.8 g, 2.3 mmol, 41%) as a white solid. m.p. 198 °C (decomp); IR (ATR)/cm–1: 2987, 2935, 2879, 1720; 
1H NMR (400 MHz, CDCl3) δ 7.86–7.82 (m, 2H), 7.72–7.67 (m, 2H), 7.59–7.56 (m, 2H), 7.53–7.50 (m, 
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2H), 7.44–7.40 (m, 2H), 7.38–7.36 (m, 2H), 7.35–7.30 (m, 1H), 6.47 (d, J = 15.8 Hz, 1H), 6.22 (d, J = 
15.8, 7.1 Hz, 1H), 3.87 (t, J = 7.1 Hz, 2H), 2.67–2.61 (m, 2H); 13C NMR (101 MHz, CDCl3) δ 168.5, 
140.9, 140.2, 136.5, 134.1, 132.31, 132.26, 128.9, 127.3, 127.1, 126.7, 126.5, 123.4, 37.7, 32.5 (1 carbon 
missing); LRMS (ES + APCI) m/z: 371.1 [M+NH4]+; HRMS (ESI-TOF) m/z: [M+H]+ calcd. for 
C24H20NO2 354.1494; found 354.1491. 
(E)-2-(4-(4-(1,3-Dioxalan-2-yl)phenyl)but-3-en-1-yl)isoindoline-1,3-dione. 2-(4-Iodophenyl)-1-dioxa-
lane (3.0 g, 10.9 mmol) and Et3N (2.8 mL, 19.7 mmol) were dissolved in MeCN (200 mL) followed by 
addition of 2-(but-3-en-1-yl)isoindoline-1,3-dione (2.0 g, 9.9 mmol), P(o-tol)3 (301 mg, 1.0 mmol) and 
Pd(OAc)2 (111 mg, 0.5 mmol) according to General Procedure 1 and the resulting mixture was heated at 
reflux for 72 h. Purification by silica gel flash column chromatography (hexane:EtOAc 9:1) afforded the 
title compound (1.6 g, 4.6 mmol, 46%) as a white solid. m.p. 120–121 °C; IR (ATR)/cm–1: 3026, 2945, 
2883, 1706; 1H NMR (500 MHz, CDCl3) δ 7.84–7.80 (m, 2H), 7.71–7.67 (m, 2H), 7.38 (d, J = 8.2 Hz, 
2H), 7.30 (d, J = 8.2 Hz, 2H), 6.42 (d, J = 15.8 Hz, 1H), 6.19 (dd, J = 15.8, 7.1 Hz, 1H), 5.78 (s, 1H), 
4.12–4.10 (m, 2H), 4.04–4.00 (m, 2H), 3.85 (d, J = 7.1 Hz, 2H), 2.63–2.59 (m, 2H); 13C NMR (101 MHz, 
CDCl3) δ 168.5, 138.4, 136.9, 134.1, 132.4, 132.2, 127.0, 126.8, 126.3, 123.4, 103.7, 65.4, 37.7, 32.4; 
LRMS (ES + APCI) m/z: 350.0 [M+H]+; HRMS (ESI-TOF) m/z: [M+H]+ calcd. for C21H20NO4 350.1392; 
found 350.1387. 
(E)-2-(4-(4-Trifluoromethylphenyl)but-3-en-1-yl)isoindoline-1,3-dione.24 1-Iodo-4-(trifluoromethyl)ben-
zene (803 μL, 5.5 mmol) and Et3N (1.4 mL, 9.9 mmol) were dissolved in MeCN (100 mL) followed by 
addition of 2-(but-3-en-1-yl)isoindoline-1,3-dione (1.0 g, 5.0 mmol), P(o-tol)3 (151 mg, 0.5 mmol) and 
Pd(OAc)2 (56 mg, 0.3 mmol) according to General Procedure 1 and the resulting mixture was heated at 
reflux for 18 h. Purification by silica gel flash column chromatography (hexane:EtOAc 9:1) afforded the 
title compound (1.2 g, 3.5 mmol, 70%) as a white solid. m.p. 150 °C decomp; IR (ATR)/cm–1: 2997, 2866, 
1699; 1H NMR (500 MHz, CDCl3) δ 7.84–7.83 (m, 2H), 7.71–7.69 (m, 2H), 7.52 (d, J = 8.1 Hz, 2H), 
7.38 (d, J = 8.1 Hz, 2H), 6.45 (d, J = 15.8 Hz, 1H), 6.31–6.25 (m, 1H), 3.87 (t, J = 7.0 Hz, 2H), 2.66–
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2.62 (m, 2H); 13C NMR (126 MHz, CDCl3) δ 168.5, 140.8, 134.2, 134.1, 132.2, 131.5, 129.3, 127.7 (JC-F 
= 348.5 Hz), 126.4, 125.6 (JC-F = 3.75 Hz), 123.4, 37.5, 32.4; LRMS (ES + APCI) m/z: 346.0 [M+H]+. 
Synthesis of 2-(4,4-diphenylbut-3-en-1-yl)isoindoline-1,3-dione.17,25–27 To a three-neck round-bottom 
flask dried and flushed with argon was added (3 hydroxypropyl)triphenylphosphonium bromide (2.6 g, 
6.6 mmol) in anhydrous THF (12 mL). The resulting suspension was cooled to -10 °C using a NaCl/ice 
bath. A 1 M solution of LiHMDS (15 mL) was added dropwise and the mixture was stirred at -10 °C for 
1 h. Benzophenone (1.0 g, 5.5 mmol) was then added dropwise and stirred at -10 °C for 2 h. The mixture 
was allowed to warm to rt and stirred for a further 18 h. A saturated aqueous solution of NH4Cl (50 mL) 
was then added. The organic layer was extracted with Et2O (2 × 100 mL), dried over MgSO4, filtered and 
the solvent was removed under reduced pressure. Purification by silica gel flash column chromatography 
(petroleum ether (40–60 °C):EtOAc 6:4) afforded 4,4 diphenylbut 3-en-1-ol (1.0 g, 4.5 mmol, 81%) as a 
colourless oil. 1H NMR (400 MHz, CDCl3) δ 7.40–7.36 (m, 2H), 7.34–7.26 (m, 2H), 7.25–7.19 (m, 6H), 
6.15 (t, J = 7.5 Hz, 1H), 3.75 (t, J = 6.5 Hz, 2H), 2.46–2.41 (m, 2H), 1.39 (bs, 1H); 13C NMR (101 MHz, 
CDCl3) δ 144.3, 142.4, 139.8, 129.9, 128.2, 128.1, 127.2, 127.1, 125.2, 62.6, 33.3. 
To a solution of 4,4-diphenylbut-3-en-1-ol (300 mg, 1.3 mmol) in a 48% solution of HBr (1.6 mL) was 
added tetrabutylammonium bromide (17 mg, 0.1 mmol). The mixture was stirred at reflux for 18 h. The 
mixture was then allowed to cool to rt and diluted with CH2Cl2 (10 mL) and H2O (10 mL). The organic 
layer was extracted with CH2Cl2 (2 × 20 mL), washed with NaHCO3 (50 mL), brine (50 mL), dried over 
MgSO4 and filtered. The solvent was removed under reduced pressure to afford (4-bromobut-1-ene-1,1-
diyl)dibenzene (350 mg, 1.2 mmol, 91%) as a yellow oil. 1H NMR (400 MHz, CDCl3) δ 7.44–7.27 (m, 
5H), 7.25–7.22 (m, 3H), 7.19–7.17 (m, 2H), 6.09 (t, J = 7.3 Hz, 1H), 3.43 (t, J = 7.0 Hz, 2H), 2.71–2.66 
(m, 2H); 13C NMR (101 MHz, CDCl3) δ 144.3, 142.1, 139.6, 129.7, 128.3, 128.1, 127.29, 127.26, 125.7, 
32.9, 32.6. 
A dry three-neck flask was charged with potassium phthalimide (360 mg, 1.9 mmol) in anhydrous DMF 
(10 mL). (4-bromobut-1-ene-1,1diyl)dibenzene (558 mg, 1.9 mmol) was added and mixture was stirrer at 
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reflux for 18 h. The mixture was allowed to cool to rt, poured into ice and extracted with CH2Cl2 (3 × 50 
mL). The organics were washed with 0.2 M KOH (50 mL), H2O (50 mL), dried over MgSO4, filtered and 
the solvent was removed under reduced pressure. Purification by silica gel flash column chromatography 
(petroleum ether (40–60 °C):EtOAc 9:1) afforded the title compound (600 mg, 1.7 mmol, 88%) as a white 
solid. m.p. 120–121 °C, Lit28 [119–120 °C]; IR (ATR)/cm–1: 2967, 2921, 2908, 2872, 1718, 1701; 1H 
NMR (400 MHz, CDCl3) δ 7.83–7.78 (m, 2H), 7.71–7.66 (m, 2H), 7.27–7.18 (m, 8H), 7.02–6.99 (m, 2H), 
6.07 (t, J = 7.6 Hz, 1H), 3.81–3.78 (m, 2H), 2.57–2.52 (m, 2H); 13C NMR (101 MHz, CDCl3) δ 168.3, 
144.5, 142.5, 139.6, 134.0, 132.3, 129.8, 128.3, 128.2, 127.5, 127.2, 125.2, 123.3, 37.8, 29.0 (1 carbon 
missing); LRMS (ES + APCI) m/z: 354.0 [M+H]+. 
General Procedure 2: Removal of phthalimide and tosylation.29 To a solution of the (E)-2-(4-arylbut-3-
en-1-yl)isoindoline-1,3-dione (1.0 equiv) in EtOH (0.3 M) was added hydrazine monohydrate (2.0 equiv). 
The mixture was stirred at room temperature for 10 min and at reflux for a further 30 minutes. After 
cooling to room temperature a 2 M solution of NaOH was added (50 mL). The solvent was evaporated 
before extracting the organics with EtOAc (3 × 50 mL) and drying over MgSO4. The solvent was removed 
by rotary evaporation to give the free amine compound which was used without further purification. The 
crude reaction mixture was dissolved in anhydrous CH2Cl2 (0.3 M) under an argon atmosphere and Et3N 
(1.5 equiv) was added. The mixture was cooled to 0 °C, and p-toluenesulfonyl chloride (1.0 equiv) and 
DMAP (0.3 equiv) were added in one portion. The mixture was stirred at room temperature for 24 h. The 
solution was diluted with CH2Cl2 and washed with 2 M HCl (100 mL) and brine (100 mL). The organics 
were dried over MgSO4 and the solvent was removed by rotary evaporation to give a crude material which 
was purified by silica gel chromatography eluting with hexane:EtOAc mixtures to afford the tosylated 
compound. 
(E)-4-Methyl-N-(4-phenylbut-3-en-1-yl)benzenesulfonamide (8a).29 To a solution of (E)-2-(4-phenylbut-
3-en-1-yl)isoindoline-1,3-dione (2.2 g, 7.4 mmol) in EtOH (32 mL) was added hydrazine monohydrate 
(771 μL, 15.8 mmol) according to General Procedure 2 to give (E)-4-phenylbut-3-en-1-amine. 
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To a solution of (E)-4-phenylbut-3-en-1-amine (1.2 g, 7.9 mmol) in CH2Cl2 (65 mL) was added Et3N (2.3 
mL, 16.2 mmol) followed by p-TsCl (1.8 g, 9.8 mmol) and DMAP (0.6 g, 4.9 mmol) according to General 
Procedure 2. Purification by silica gel flash column chromatography (hexane:EtOAc 9:1) afforded the 
title compound 8a (1.8 g, 6.0 mmol, 74%) as a white solid. m.p. 52–54 °C; IR (ATR)/cm–1: 3272, 3058, 
3023, 2922; 1H NMR (500 MHz, CDCl3) δ 7.75 (d,  J = 8.2 Hz, 2H), 7.31–7.27 (m, 6H), 7.24–7.21 (m, 
1H), 6.36 (d, J = 15.9 Hz, 1H), 5.98 (dt, J = 15.9, 7.1 Hz, 1H), 4.43 (bs, 1H), 3.13–3.09 (m, 2H), 2.43 (s, 
3H), 2.39–2.35 (m, 2H); 13C NMR (126 MHz, CDCl3) δ 143.6, 137.2, 136.9, 133.5, 129.9, 128.7, 127.7, 
127.3, 126.3, 125.6, 42.7, 33.2, 21.7; LRMS (ES + APCI) m/z: 319.1 [M+NH4]+. 
(E)-4-Methyl-N-(4-(p-tolyl)but-3-en-1-yl)benzenesulfonamide.30 To a solution of (E)-2-(4-(p-tolyl)but-3-
en-1-yl)isoindoline-1,3-dione (430 mg, 1.5 mmol) in EtOH (6.0 mL) was added hydrazine monohydrate 
(143 μL, 3.0 mmol) according to General Procedure 2 to give (E)-4-(p-tolylbut)-3-en-1-amine. 
To a solution of (E)-4-(p-tolylbut)-3-en-1-amine (165 mg, 1.0 mmol) in CH2Cl2 (4.0 mL) was added Et3N 
(210 μL, 1.5 mmol) followed by p-TsCl (190 mg, 1.2 mmol) and DMAP (37 mg, 0.3 mmol) according to 
General Procedure 2. Purification by silica gel flash column chromatography (hexane:EtOAc 8:2) af-
forded the title compound (192 mg, 0.6 mmol, 61%) as a white solid. m.p. 82–84 °C; IR (ATR)/cm–1: 
3276, 3047, 3017, 2939; 1H NMR (500 MHz, CDCl3) δ 7.74 (d, J = 8.2 Hz, 2H), 7.29 (d, J = 8.2 Hz, 2H), 
7.17 (d, J = 8.0 Hz, 2H), 7.10 (d, J = 8.0 Hz, 2H), 6.32 (d, J = 15.8 Hz, 1H), 5.97 (dt, J = 15.8, 7.1 Hz, 
1H), 4.37 (t, J = 5.4 Hz, 1H), 3.12–3.08 (m, 2H), 2.43 (s, 3H), 2.37–2.34 (m, 2H), 2.33 (s, 3H); 13C NMR 
(126 MHz, CDCl3) δ 143.6, 137.5, 137.2, 134.1, 133.4, 129.9, 129.4, 127.3, 126.2, 124.5, 42.7, 33.1, 21.7, 
21.3; LRMS (ES + APCI) m/z: 316.0 [M+H]+. 
(E)-4-Methyl-N-(4-(m-tolyl)but-3-en-1-yl)benzenesulfonamide.21 To a solution of (E)-2-(4-(m-tolyl)but-
3-en-1-yl)isoindoline-1,3-dione (340 mg, 1.2 mmol) in EtOH (4.5 mL) was added hydrazine monohydrate 
(113 μL, 2.3 mmol) according to General Procedure 2 to give (E)-4-(m-tolylbut)-3-en-1-amine. 
To a solution of (E)-4-(m-tolylbut)-3-en-1-amine (189 mg, 1.2 mmol) in CH2Cl2 (4.0 mL) was added Et3N 
(245 μL, 1.8 mmol) followed by p-TsCl (223 mg, 1.2 mmol) and DMAP (43 mg, 0.4 mmol) according to 
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General Procedure 2. Purification by silica gel flash column chromatography (hexane:EtOAc 8:2) af-
forded the title compound (145 mg, 0.5 mmol, 39%) as a colourless oil. IR (ATR)/cm–1: 3277, 3023, 2919, 
2861; 1H NMR (500 MHz, CDCl3) δ 7.75 (d, J = 8.2 Hz, 2H), 7.29 (d, J = 8.2 Hz, 2H), 7.18 (t, J = 7.6 
Hz, 1H), 7.10 (s, 1H), 7.08 (d, J = 7.6 Hz, 1H), 7.04 (d, J = 7.6 Hz, 1H), 6.33 (d, J = 15.8 Hz, 1H), 5.97 
(dt, J = 15.8, 7.0 Hz, 1H), 4.66 (t, J = 5.8 Hz, 1H), 3.11–3.07 (m, 2H), 2.42 (s, 3H), 2.38–2.33 (m, 2H), 
2.33 (s, 3H); 13C NMR (126 MHz, CDCl3) δ 143.5, 138.2, 137.1, 136.9, 133.4, 129.8, 128.6, 128.4, 127.3, 
127.0, 125.5, 123.4, 42.7, 33.1, 21.6, 21.5; LRMS (ES + APCI) m/z: 316.0 [M+H]+. 
(E)-4-Methyl-N-(4-(o-tolyl)but-3-en-1-yl)benzenesulfonamide.21 To a solution of (E)-2-(4-(o-tolyl)but-3-
en-1-yl)isoindoline-1,3-dione (275 mg, 0.9 mmol) in EtOH (3.6 mL) was added hydrazine monohydrate 
(92 μL, 1.9 mmol) according to General Procedure 2 to give (E)-4-(o-tolylbut)-3-en-1-amine. 
To a solution of (E)-4-(o-tolylbut)-3-en-1-amine (151 mg, 0.9 mmol) in CH2Cl2 (4.0 mL) was added Et3N 
(200 μL, 1.4 mmol) followed by p-TsCl (179 mg, 0.9 mmol) and DMAP (35 mg, 0.3 mmol) according to 
General Procedure 2. Purification by silica gel flash column chromatography (hexane:EtOAc 8:2) af-
forded the title compound (64 mg, 0.2 mmol, 22%) as a colourless oil. IR (ATR)/cm–1: 3272, 3021, 2922, 
2865; 1H NMR (500 MHz, CDCl3) δ 7.76 (d, J = 8.1 Hz, 2H), 7.32–7.31 (m, 1H), 7.28 (d, J = 8.1 Hz, 
2H), 7.15–7.11 (m, 3H), 6.58 (d, J = 15.7 Hz, 1H), 5.86 (dt, J = 15.7, 7.1 Hz, 1H), 4.65 (bs, 1H), 3.11 (t, 
J = 6.7 Hz, 2H), 2.42 (s, 3H), 2.42–2.37 (m, 2H), 2.30 (s, 3H); 13C NMR (126 MHz, CDCl3) δ 143.6, 
137.2, 136.1, 135.2, 131.2, 130.4, 129.8, 127.5, 127.4, 127.0, 126.2, 125.6, 42.8, 33.4, 21.6, 19.9; LRMS 
(ES + APCI) m/z: 316.0 [M+H]+. 
(E)-2-(4-([1,1'-Biphenyl]-4-yl)but-3-en-1-yl)-4-methylbenzenesulfonamide. To a solution of (E)-2-(4-
([1,1'-biphenyl]-4-yl)but-3-en-1-yl)isoindoline-1,3-dione (300 mg, 0.9 mmol) in EtOH (3.5 mL) was 
added hydrazine monohydrate (82 μL, 1.7 mmol) according to General Procedure 2 to give (E)-4-([1,1'-
biphenyl]-4-yl)but-3-en-1-amine. 
To a solution of (E)-4-([1,1'-biphenyl]-4-yl)but-3-en-1-amine (189 mg, 0.9 mmol) in CH2Cl2 (3.0 mL) 
was added Et3N (177 μL, 1.3 mmol) followed by p-TsCl (162 mg, 0.9 mmol) and DMAP (31 mg, 0.3 
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mmol) according to General Procedure 2. Purification by silica gel flash column chromatography (hex-
ane:EtOAc 9:1) afforded the title compound (75 mg, 0.2 mmol, 23%) as a white solid. m.p. 126–128 °C; 
IR (ATR)/cm–1: 3276, 3051, 3025, 2922, 2865; 1H NMR (500 MHz, CDCl3) δ 7.76 (d, J = 8.2 Hz, 2H), 
7.59 (d, J = 7.3 Hz, 2H), 7.54 (d, J = 8.2 Hz, 2H), 7.44 (at, J = 7.6 Hz, 2H), 7.36–7.34 (m, 3H), 7.30 (d, 
J = 8.0 Hz, 2H), 6.40 (d, J = 15.9 Hz, 1H), 6.03 (dt, J = 15.9, 7.1 Hz, 1H), 4.59 (t, J = 6.0 Hz, 1H), 3.14–
3.10 (m, 2H), 2.42 (s, 3H), 2.41–2.37 (m, 2H); 13C NMR (126 MHz, CDCl3) δ 143.6, 140.8, 140.4, 137.1, 
136.0, 132.9, 129.9, 128.9, 127.5, 127.4, 127.3, 127.0, 126.7, 125.8, 42.7, 33.2, 21.7; LRMS (ES + APCI) 
m/z: 378.0 [M+NH4]+; HRMS (ESI-TOF) m/z: [M+H]+ calcd. for C23H24NO2S 378.1528; found 378.1522. 
(E)-N-(4-(4-Chlorophenyl)but-3-en-1-yl)-4-methylbenzenesulfonamide.31 To a solution of (E)-2-(4-(4-
chlorophenyl)but-3-en-1-yl)isoindoline-1,3-dione (444 mg, 1.4 mmol) in EtOH (5.5 mL) was added hy-
drazine monohydrate (138 μL, 2.8 mmol) according to General Procedure 2 to give (E)-4-(4-chloro-
phenyl)but-3-en-1-amine. 
To a solution of (E)-4-(4-chlorophenyl)but-3-en-1-amine (150 mg, 0.8 mmol) in CH2Cl2 (3.0 mL) was 
added Et3N (172 μL, 1.2 mmol) followed by p-TsCl (157 mg, 0.8 mmol) and DMAP (30 mg, 0.3 mmol) 
according to General Procedure 2. Purification by silica gel flash column chromatography (hexane:EtOAc 
8:2) afforded the title compound (57 mg, 0.2 mmol, 20%) as a white solid. m.p. 90–92 °C; IR (ATR)/cm–
1: 3360, 3250, 2947, 2826; 1H NMR (500 MHz, CDCl3) δ 7.74 (d, J = 8.2 Hz, 2H), 7.27 (d, J = 8.2 Hz, 
2H), 7.23 (d, J = 8.5 Hz, 2H), 7.18 (d, J = 8.5 Hz, 2H), 6.30 (d, J = 15.9 Hz, 1H), 5.96 (dt, J = 15.9, 7.0 
Hz, 1H), 4.78 (t, J = 5.9 Hz, 1H), 3.10–3.07 (m, 2H), 2.41 (s, 3H), 2.37–2.33 (m, 2H); 13C NMR (126 
MHz, CDCl3) δ 143.6, 137.1, 135.5, 133.1, 132.0, 129.9, 128.8, 127.5, 127.2, 126.6, 42.6, 33.1, 21.6; 
LRMS (ES + APCI) m/z: 336.0 [M+H]+. 
(E)-N-(4-(3-Chlorophenyl)but-3-en-1-yl)-4-methylbenzenesulfonamide. To a solution of (E)-2-(4-(3-chlo-
rophenyl)but-3-en-1-yl)isoindoline-1,3-dione (1.8 g, 5.8 mmol) in EtOH (22 mL) was added hydrazine 
monohydrate (560 μL, 11.5 mmol) according to General Procedure 2 to give (E)-4-(3-chlorophenyl)but-
3-en-1-amine. 
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To a solution of (E)-4-(3-chlorophenyl)but-3-en-1-amine (1.1 g, 5.8 mmol) in CH2Cl2 (20 mL) was added 
Et3N (1.2 μL, 8.7 mmol) followed by p-TsCl (1.1 g, 5.8 mmol) and DMAP (0.2 g, 1.7 mmol) according 
to General Procedure 2. Purification by silica gel flash column chromatography (hexane:EtOAc 8:2) af-
forded the title compound (0.4 g, 1.2 mmol, 21%) as a colourless oil. IR (ATR)/cm–1: 3272, 3060, 3025, 
2921, 2870; 1H NMR (500 MHz, CDCl3) δ 7.74 (d, J = 8.0 Hz, 2H), 7.28 (d, J = 8.0 Hz, 2H), 7.24 (m, 
1H), 7.21–7.17 (m, 2H), 7.13 (d, J = 7.1 Hz, 1H), 6.29 (d, J = 15.9 Hz, 1H), 5.99 (dt, J = 15.9, 7.0 Hz, 
1H), 4.68 (bs, 1H), 3.12–3.08 (m, 2H), 2.42 (s, 3H), 2.39–2.35 (m, 2H); 13C NMR (126 MHz, CDCl3) δ 
143.6, 138.8, 137.1, 134.6, 131.9, 129.9, 127.5, 127.4, 127.3, 126.1, 124.6, 42.6, 33.1, 21.7 (1 carbon 
missing); LRMS (ES + APCI) m/z: 352.9 [M+NH4]+; HRMS (ESI-TOF) m/z: [M+H]+ calcd. for 
C17H1935ClNO2S 336.0825; found 336.0823. 
(E)-N-(4-(4-(1,3-Dioxalan-2-yl)phenyl)but-3-en-1-yl)-4-methylbenzenesulfonamide. To a solution of (E)-
2-(4-(4-(1,3-dioxalan-2-yl)phenyl)but-3-en-1-yl)isoindoline-1,3-dione (400 mg, 1.1 mmol) in EtOH (4.5 
mL) was added hydrazine monohydrate (111 μL, 2.3 mmol) according to General Procedure 2 to give (E)-
(4-(4-(1,3-dioxalan-2-yl)phenyl)but-3-en-1-yl)-1-amine. 
To a solution of (E)-(4-(4-(1,3-dioxalan-2-yl)phenyl)but-3-en-1-yl)-1-amine (250 mg, 1.1 mmol) in 
CH2Cl2 (4.0 mL) was added Et3N (240 μL, 1.7 mmol) followed by p-TsCl (217 mg, 1.1 mmol) and DMAP 
(42 mg, 0.3 mmol) according to General Procedure 2. Purification by silica gel flash column chromatog-
raphy (hexane:EtOAc 6:4) afforded the title compound (260 mg, 0.7 mmol, 61%) as a colourless oil. IR 
(ATR)/cm–1: 3264, 3026, 2948, 2883; 1H NMR (500 MHz, CDCl3) δ 7.74 (d, J = 8.3 Hz, 2H), 7.40 (d, J 
= 8.2 Hz, 2H), 7.30–7.27 (m, 4H), 6.36 (d, J = 15.9 Hz, 1H), 5.99 (dt, J = 15.8, 7.1 Hz, 1H), 5.79 (s, 1H), 
4.43 (t, J = 5.8 Hz, 1H), 4.15–4.11 (m, 2H), 4.05–4.01 (m, 2H), 3.13–3.08 (m, 2H), 2.42 (s, 3H), 2.39–
2.34 (m, 2H); 13C NMR (101 MHz, CDCl3) δ 143.6, 137.8, 137.3, 137.1, 133.0, 130.0, 127.3, 126.9, 
126.33, 126.26, 103.7, 65.4, 42.6, 33.2, 21.7; LRMS (ES + APCI) m/z: 374.0 [M+H]+; HRMS (ESI-TOF) 
m/z: [M+H]+ calcd. for C20H24NO4S 374.1426; found 374.1420. 
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(E)-4-Methyl-N-(4-(4-trifluoromethyl)phenyl)but-3-en-1-yl)benzenesulfonamide. To a solution of (E)-2-
(4-(4-trifluoromethylphenyl)but-3-en-1-yl)isoindoline-1,3-dione (1.0 g, 2.9 mmol) in EtOH (11 mL) was 
added hydrazine monohydrate (280 μL, 5.8 mmol) according to General Procedure 2 to give (E)-4-(4-
(trifluoro)phenyl)but-3-en-1-amine. 
To a solution of (E)-4-(4-(trifluoro)phenyl)but-3-en-1-amine (623 mg, 3.0 mmol) in CH2Cl2 (9.6 mL) was 
added Et3N (604 μL, 4.3 mmol) followed by p-TsCl (551 mg, 2.9 mmol) and DMAP (106 mg, 0.9 mmol) 
according to General Procedure 2. Purification by silica gel flash column chromatography (hexane:EtOAc 
8:2) afforded the title compound (409 mg, 1.1 mmol, 38%) as a white solid. m.p. 121–122 °C; IR 
(ATR)/cm–1: 3330, 3244, 2991, 2875; 1H NMR (500 MHz, CDCl3) δ 7.74 (d,  J = 8.1 Hz, 2H), 7.55 (d, J 
= 8.1 Hz, 2H), 7.37 (d, J = 8.0 Hz, 2H), 7.29 (d, J = 8.0 Hz, 2H), 6.40 (d, J = 15.9 Hz, 1H), 6.14–6.08 
(m, 1H), 4.39 (t, J = 5.9 Hz, 1H), 3.15–3.11 (m, 2H), 2.42 (s, 3H), 2.42–2.39 (m, 2H); 13C NMR (126 
MHz, CDCl3) δ 143.7, 140.4, 137.1, 132.0, 129.9, 129.4 (d, JC-F = 33.1 Hz), 128.7, 127.3, 126.4, 125.6 
(q, JC-F = 3.7 Hz), 124.3 (d, JC-F = 272.0 Hz), 42.6, 33.3, 21.6; LRMS (ES + APCI) m/z: 370.0 [M+H]+. 
N-(4,4-Diphenylbut-3-en-1-yl)-4-methylbenzenesulfonamide. To a solution of 2-(4,4-diphenylbut-3-en-1-
yl)isoindoline-1,3-dione (280 mg, 0.8 mmol) in EtOH (3.0 mL) was added hydrazine monohydrate (77 
μL, 1.6 mmol) according to General Procedure 2 to give 4,4-diphenylbut-3-en-1-amine. 
To a solution of 4,4-diphenylbut-3-en-1-amine (176 mg, 0.8 mmol) in CH2Cl2 (2.6 mL) was added Et3N 
(165 μL, 1.2 mmol) followed by p-TsCl (166 mg, 0.9 mmol) and DMAP (29 mg, 0.2 mmol) according to 
General Procedure 2. Purification by silica gel flash column chromatography (hexane:EtOAc 8:2) af-
forded the title compound (200 mg, 0.5 mmol, 67%) as a colourless oil. IR (ATR)/cm–1: 3281, 3053, 3023, 
2922; 1H NMR (500 MHz, CDCl3) δ 7.72 (d, J = 8.3 Hz, 2H), 7.38–7.29 (m, 3H), 7.27–7.22 (m, 5H), 
7.20–7.15 (m, 2H), 7.12–7.10 (m, 2H), 5.97 (t, J = 7.4 Hz, 1H), 4.76 (bs, 1H), 3.07–3.02 (m, 2H), 2.41 
(s, 3H), 2.30–2.24 (m, 2H); 13C NMR (101 MHz, CDCl3) δ 144.7, 143.4, 142.1, 139.6, 137.0, 129.8, 
128.4, 128.2, 127.35, 127.31, 127.2, 124.7, 43.1, 29.9, 21.6; LRMS (ES + APCI) m/z: 378.1 [M+H]+; 
HRMS (ESI-TOF) m/z: [M+H]+ calcd. for C23H24NO2S 378.1528; found 378.1521. 
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(E)-(4-phenylbut-3-en-1-yl)acetamide (8b).32 To a cooled (0 °C) solution of (E)-4-phenylbut-3-en-1-
amine (200 mg, 1.4 mmol) in CH2Cl2 (6 mL) was added Et3N (206 μL, 2.0 mmol) followed by addition 
of acetyl chloride (97 μL, 1.4 mmol). The resultant mixture was then stirred at rt for 18 h, before washing 
with a 1 M HCl solution (20 mL) followed by 1 M NaOH solution (20 mL) and brine (20 mL). The organic 
layer was dried over MgSO4, filtered and the solvent was removed by rotary evaporation affording the 
title compound 8b (190 mg, 1.0 mmol, 72%) as a yellow semi-solid. 1H NMR (400 MHz, CDCl3) 7.35–
7.28 (m, 4H), 7.22 (t, J = 7.1 Hz, 1H), 6.45 (d, J = 15.8 Hz, 1H), 6.14 (dt, J = 15.8, 7.1 Hz, 1H), 5.62 (bs, 
1H), 3.42–3.37 (m, 2H), 2.45–2.39 (m, 2H), 1.96 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 170.2, 137.3, 
132.5, 128.7, 127.5, 127.0, 126.2, 39.1, 33.2, 23.5; LRMS (ES + APCI) m/z: 190.1 [M+H]+. 
tert-Butyl (E)-(4-phenylbut-3-en-1-yl)carbamate (8c).33 To a solution of (E)-4-phenylbut-3-en-1-amine 
(316 mg, 2.1 mmol) in CH2Cl2 (4 mL) was added K2CO3 (591 mg, 4.3 mmol) followed by addition of di-
tert-butyl dicarbonate (468 mg, 2.1 mmol). The resultant mixture was then stirred at 40 °C for 18 h, before 
the addition of H2O (20 mL) and the stirring was extended for an extra hour. Layers were separated and 
the organic layer was washed with brine (30 mL), dried over MgSO4, filtered and the solvent was removed 
by rotary evaporation. Purification by silica gel flash column chromatography (hexane:EtOAc 9:1) af-
forded the title compound 8c (441 mg, 1.8 mmol, 83%) as a colourless oil. 1H NMR (400 MHz, CDCl3) 
δ 7.35–7.34 (m, 2H), 7.30 (at, J = 7.5 Hz, 2H), 7.21 (t, J = 7.1 Hz, 1H), 6.45 (d, J = 15.8 Hz, 1H), 6.15 
(dt, J = 15.8, 7.1 Hz, 1H), 4.59 (bs, 1H), 3.30–3.25 (m, 2H), 2.43–2.38 (m, 2H), 1.44 (s, 9H); 13C NMR 
(101 MHz, CDCl3) δ 156.1, 137.4, 132.4, 128.7, 127.4, 127.2, 126.2, 40.2, 33.7, 28.6 (1 carbon missing); 
LRMS (ES + APCI) m/z: 248.1 [M+H]+. 
Benzyl (E)-(4-phenylbut-3-en-1-yl)carbamate (8d).21 To a solution of (E)-4-phenylbut-3-en-1-amine (308 
mg, 2.1 mmol) in H2O (10 mL) and acetone (21 mL) was added NaHCO3 (200 mg, 2.4 mmol) followed 
by addition of benzyl chloroformate (335 μL, 2.4 mmol). The resultant mixture was then stirred at rt for 
18 h, before evaporation of the solvent and the precipitate was filtered affording the title compound 8d 
(498 mg, 1.8 mmol, 85%) as a white solid. m.p. 90–92 °C; 1H NMR (400 MHz, CDCl3) δ 7.35–7.28 (m, 
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9H), 7.24–7.1 (m, 1H), 6.45 (d, J = 15.9 Hz, 1H), 6.14 (dt, J = 15.9, 7.3 Hz, 1H), 5.10 (s, 2H), 4.83 (bs, 
1H), 3.38–3.34 (m, 2H), 2.46–2.41 (m, 2H); 13C NMR (101 MHz, CDCl3) δ 156.3, 137.1, 136.6, 132.5, 
128.6, 128.5, 128.5, 128.1, 127.3, 126.6, 126.1, 66.6, 40.5, 33.5; LRMS (ES + APCI) m/z: 282.1 [M+H]+. 
(E)-2,4-Dinitro-N-(4-phenylbut-3-en-1-yl)benzenesulfonamide (8e). To a cooled (0 °C) solution of (E)-4-
phenylbut-3-en-1-amine (200 mg, 1.4 mmol) in CH2Cl2 (14 mL) was added Et3N (284 μL, 2.0 mmol) 
followed by addition of 2,4-dinitrobenzenesulfonyl chloride (471 mg, 1.8 mmol). The resultant mixture 
was then stirred at rt for 18 h, before quenching with a saturated solution of NH4Cl (20 mL). The organic 
layer was extracted with CH2Cl2 (3 × 50 mL), washed with brine (100 mL), dried over MgSO4, filtered 
and the solvent was removed by rotary evaporation. Purification by silica gel flash column chromatog-
raphy (hexane:EtOAc 8:2) afforded the title compound 8e (502 mg, 1.3 mmol, 98%) as a yellow solid. 
m.p. 130–132 °C; 1H NMR (400 MHz, CDCl3) δ 8.37 (s, 1H), 8.36–8.34 (m, 1H), 8.27–8.24 (m, 1H), 
7.24–7.15 (m, 3H), 7.11–7.08 (m, 2H), 6.29 (d, J = 15.8 Hz, 1H), 5.83 (dt, J = 15.8, 7.3 Hz, 1H), 5.41 
(bt, J = 5.6 Hz, 1H), 3.46–3.42 (m, 2H), 2.46–2.41 (m, 2H); 13C NMR (101 MHz, CDCl3) δ 149.2, 147.7, 
139.8, 136.2, 133.8, 131.9, 128.6, 128.1, 127.0, 125.9, 125.1, 120.7, 43.9, 33.5; LRMS (ES + APCI) m/z: 378.1 
[M+H]+; HRMS (ESI-TOF) m/z: [M+H]+ calcd. for C16H16N3O6S 378.0760; found 378.0746. 
General Procedure 3: Oxyamination procedure for the synthesis of pyrrolidines. Malonoyl peroxide 1 
(1.5 equiv) was added to a solution of alkene 11 (1.0 equiv) in HFIP (0.5 M). The mixture was stirred at 
rt for 5 h. The solvent was removed by rotary evaporation and the resulting residue was directly treated 
with 1 M NaOH:THF (1:1 (0.1 M)). The solution was stirred at 60 °C for 18 h, allowed to cool to rt and 
the aqueous phase was extracted with EtOAc (× 3). The combined organics were washed with brine and 
dried over MgSO4. Removal of the solvent under reduced pressure afforded the crude pyrrolidine product. 
Purification by silica gel flash column chromatography eluting with hexane:EtOAc mixtures afforded the 
target compound 12. 
(±)-2-Phenyl-1-tosylpyrrolidin-3-ol (9a).34 Reaction of (E)-4-methyl-N-(4-phenylbut-3-en-1-yl)benzene-
sulfonamide 8a (25 mg, 0.08 mmol) and malonoyl peroxide 1 (16 mg, 0.12 mmol) in HFIP (0.2 mL) 
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according to General Procedure 3 followed by hydrolysis in 1 M NaOH:THF (0.8 mL, 1:1) gave the crude 
alcohol (1:13 cis:trans). Purification by silica gel flash column chromatography (hexane:EtOAc 4:6) gave 
the title compound 9a (18 mg, 0.06 mmol, 71%) as a white solid. m.p. 148–149 °C, Lit34 [155–156 °C]; 
IR (ATR)/cm–1: 3474, 3065, 3034, 2929, 2892; 1H NMR (500 MHz, CDCl3) δ 7.75 (d, J = 8.1 Hz, 2H), 
7.34–7.33 (m, 4H), 7.31 (d, J = 8.1 Hz, 2H), 7.28–7.26 (m, 1H), 4.66 (bs, 1H), 4.18 (bs, 1H), 3.73 (td, J 
= 9.4, 2.1 Hz, 1H), 3.53 (td, J = 9.9, 7.0 Hz, 1H), 2.43 (s, 3H), 2.07–2.00 (m, 1H), 1.77–1.73 (m, 1H), 
1.37–1.38 (m, 1H); 13C NMR (126 MHz, CDCl3) δ 143.7, 139.9, 134.7, 129.7, 128.7, 128.9, 127.7, 126.3, 
79.1, 72.0, 46.8, 31.5, 21.7; LRMS (ES + APCI) m/z: 318.0 [M+H]+. 
(±)-2-(p-Tolyl)-1-tosylpyrrolidin-3-ol (13). Reaction of (E)-4-methyl-N-(4-(p-tolyl)but-3-en-1-yl)ben-
zenesulfonamide (100 mg, 0.32 mmol) and malonoyl peroxide 1 (61 mg, 0.48 mmol) in HFIP (0.7 mL) 
according to General Procedure 3 followed by hydrolysis in 1 M NaOH:THF (3.2 mL, 1:1) gave the crude 
alcohol (1:7 cis:trans). Purification by silica gel flash column chromatography (hexane:EtOAc 4:6) gave 
the title compound 13 (69 mg, 0.21 mmol, 66%) as a white solid. m.p. 135–136 °C; IR (ATR)/cm–1: 3401, 
3029, 2960, 2899; 1H NMR (400 MHz, CDCl3) δ 7.73 (d, J = 8.2 Hz, 2H), 7.29 (d, J = 8.0 Hz, 2H), 7.22 
(d, J = 8.2 Hz, 2H), 7.13 (d, J = 8.0 Hz, 2H), 4.62 (bs, 1H), 4.13 (bs, 1H), 3.70 (ddd, J = 9.3, 8.6, 2.4 Hz, 
1H), 3.50 (td, J = 9.9, 6.9 Hz, 1H), 2.42 (s, 3H), 2.33 (s, 3H), 2.07–1.97 (m, 1H), 1.75–1.69 (m, 1H), 1.54 
(bs, 1H); 13C NMR (101 MHz, CDCl3) δ 143.6, 137.3, 137.1, 134.7, 129.7, 129.3, 127.9, 126.2, 79.0, 
71.8, 46.8, 31.5, 21.7, 21.2; LRMS (ES + APCI) m/z: 332.0 [M+H]+; HRMS (ESI-TOF) m/z: [M+H]+ 
calcd. for C18H22NO3S 332.1320; found 332.1316. 
(±)-2-(m-Tolyl)-1-tosylpyrrolidin-3-ol (14). Reaction of (E)-4-methyl-N-(4-(m-tolyl)but-3-en-1-yl)ben-
zenesulfonamide (50 mg, 0.16 mmol) and malonoyl peroxide 1 (30 mg, 0.24 mmol) in HFIP (0.3 mL) 
according to General Procedure 3 followed by hydrolysis in 1 M NaOH:THF (1.9 mL, 1:1) gave the crude 
alcohol (1:6 cis:trans). Purification by silica gel flash column chromatography (hexane:EtOAc 4:6) gave 
the title compound 14 (37 mg, 0.11 mmol, 71%) as a white solid. m.p. 102–104 °C; IR (ATR)/cm–1: 3525, 
3489, 3478. 3462, 3447, 2950, 2921; 1H NMR (400 MHz, CDCl3) δ 7.73 (d, J = 8.3 Hz, 2H), 7.29 (d, J 
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= 8.3 Hz, 2H), 7.21 (at, J = 7.5 Hz, 1H), 7.12–7.10 (m, 2H), 7.06 (d, J = 7.4 Hz, 1H), 4.63 (bs, 1H), 4.14 
(bs, 1H), 3.71 (ddd, J = 9.4, 8.5, 2.4 Hz, 1H), 3.53 (td, J = 9.9, 6.9 Hz, 1H), 2.42 (s, 3H), 2.32 (s, 3H), 
2.07–1.98 (m, 1H), 1.76–1.70 (m, 1H), 1.55 (bd, J = 2.6 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ 143.6, 
139.9, 138.3, 134.8, 129.7, 128.6, 128.4, 127.8, 127.0, 123.4, 79.0, 72.0, 46.9, 31.5, 21.7, 21.6; LRMS 
(ES + APCI) m/z: 332.0 [M+H]+; HRMS (ESI-TOF) m/z: [M+H]+ calcd. for C18H22NO3S  332.1320; 
found 332.1316. 
(±)-2-(o-Tolyl)-1-tosylpyrrolidin-3-ol (15). Reaction of (E)-4-methyl-N-(4-(o-tolyl)but-3-en-1-yl)ben-
zenesulfonamide (100 mg, 0.32 mmol) and malonoyl peroxide 1 (61 mg, 0.48 mmol) in HFIP (0.6 mL) 
according to General Procedure 3 followed by hydrolysis in 1 M NaOH:THF (3.2 mL, 1:1) gave the crude 
alcohol (1:4.6 cis:trans). Purification by silica gel flash column chromatography (hexane:EtOAc 4:6) gave 
the title compound 15 (76 mg, 0.23 mmol, 72%) as a white solid. m.p. 173–175 °C; IR (ATR)/cm–1: 3504, 
3064, 2948, 2922, 2854; 1H NMR (400 MHz, CDCl3) δ 7.75 (d, J = 8.1 Hz, 2H), 7.36–7.34 (m, 1H), 7.30 
(d, J = 8.1 Hz, 2H), 7.20–7.12 (m, 3H), 4.85 (bs, 1H), 4.06 (bs, 1H), 3.76 (td, J = 8.9, 1.6 Hz, 1H), 3.54 
(ddd, J = 11.0, 9.3, 6.7 Hz, 1H), 2.42 (s, 3H), 2.38 (s, 3H), 2.10–2.01 (m, 1H), 1.79–1.74 (m, 1H), 1.59 
(bs, 1H); 13C NMR (150 MHz, CDCl3) δ 143.6, 138.2, 134.8, 134.4, 130.5, 129.7, 127.8, 127.5, 126.4, 
126.2, 77.6, 69.7, 46.9, 31.5, 21.7, 19.6; LRMS (ES + APCI) m/z: 332.0 [M+H]+; HRMS (ESI-TOF) m/z: 
[M+H]+ calcd. for C18H22NO3S 332.1320; found 332.1317. 
(±)-2-([1,1'-Biphenyl]-4-yl)-1-tosylpyrrolidin-3-ol (16). Reaction of (E)-2-(4-([1,1'-biphenyl]-4-yl)but-3-
en-1-yl)-4-methylbenzenesulfonamide (40 mg, 0.11 mmol) and malonoyl peroxide 1 (20 mg, 0.16 mmol) 
in HFIP (0.2 mL) according to General Procedure 3 followed by hydrolysis in 1 M NaOH:THF (1.0 mL, 
1:1) gave the crude alcohol (1:9 cis:trans). Purification by silica gel flash column chromatography (hex-
ane:EtOAc 4:6) gave the title compound 16 (30 mg, 0.08 mmol, 72%) as a white solid. m.p. 190–192 °C, 
decomp.; IR (ATR)/cm–1: 3450, 3010, 2947, 2920; 1H NMR (500 MHz, CDCl3) δ 7.76 (d, J = 8.1 Hz, 
2H), 7.50–7.47 (m, 4H), 7.45–7.40 (m, 4H), 7.29–7.23 (m, 3H), 4.70 (bs, 1H), 4.22 (bs, 1H), 3.77–3.73 
(m, 1H), 3.55 (dt, J = 16.8, 8.5 Hz, 1H), 2.43 (s, 3H), 2.11–2.05 (m, 1H), 1.79–1.75 (m, 1H), 1.50 (bs, 
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1H); 13C NMR (126 MHz, CDCl3) δ 143.7, 140.9, 140.7, 139.0, 134.7, 129.7, 128.9, 127.9, 127.5, 127.3, 
126.8, 79.1, 71.8, 46.9, 31.6, 21.7 (missing 1 carbon); LRMS (ES + APCI) m/z: 394.0 [M+H]+; HRMS 
(ESI-TOF) m/z: [M+H]+ calcd. for C23H24NO3S 394.1477; found 394.1472. 
(±)-2-(4-Chlorophenyl)-1-tosylpyrrolidin-3-ol (17). Reaction of (E)-N-(4-(4-chlorophenyl)but-3-en-1-
yl)-4-methylbenzenesulfonamide (100 mg, 0.30 mmol) and malonoyl peroxide 1 (57 mg, 0.45 mmol) in 
HFIP (0.6 mL) according to General Procedure 3 followed by hydrolysis in 1 M NaOH:THF (2.6 mL, 
1:1) gave the crude alcohol (1:9 cis:trans). Purification by silica gel flash column chromatography (hex-
ane:EtOAc 4:6) gave the title compound 17 (69 mg, 0.20 mmol, 67%) as a white solid. m.p. 169–171 °C; 
IR (ATR)/cm–1: 3558, 3499, 2937, 2889; 1H NMR (500 MHz, CDCl3) δ 7.72 (d, J = 7.7 Hz, 2H), 7.31–
7.26 (m, 6H), 4.60 (bs, 1H), 4.11 (bs, 1H), 3.72–3.69 (m, 1H), 3.52–3.47 (m, 1H), 2.42 (s, 3H), 2.02–1.95 
(m, 1H), 1.75–1.72 (m, 1H), 1.58 (bs, 1H); 13C NMR (126 MHz, CDCl3) δ 143.8, 138.6, 134.4, 129.8, 
128.8, 128.9, 127.9, 127.7, 78.9, 71.4, 46.9, 31.5, 21.7; LRMS (ES + APCI) m/z: 351.9 [M]+; HRMS 
(ESI-TOF) m/z: [M+H]+ calcd. for C17H1935ClNO3S 352.0774; found 352.0772. 
(±)-2-(3-Chlorophenyl)-1-tosylpyrrolidin-3-ol (18). Reaction of (E)-N-(4-(3-chlorophenyl)but-3-en-1-
yl)-4-methylbenzenesulfonamide (60 mg, 0.18 mmol) and malonoyl peroxide 1 (34 mg, 0.27 mmol) in 
HFIP (0.4 mL) according to General Procedure 3 followed by hydrolysis in 1 M NaOH:THF (0.4 mL, 
1:1) gave the crude alcohol (1:6 cis:trans). Purification by silica gel flash column chromatography (hex-
ane:EtOAc 4:6) gave the title compound 18 (33 mg, 0.09 mmol, 52%) as a white solid. m.p. 96–98 °C; IR 
(ATR)/cm–1: 3489, 3062, 2952, 2922, 2954; 1H NMR (500 MHz, CDCl3) δ 7.72 (d, J = 8.1 Hz, 2H), 7.29 
(d, J = 8.1 Hz, 2H), 7.27 (s, 1H), 7.25–7.21 (m, 3H), 4.63 (bs, 1H), 4.12 (bs, 1H), 3.70 (td, J = 9.3, 2.3 
Hz, 1H), 3.52 (td, J = 9.9, 6.9 Hz, 1H), 2.42 (s, 3H), 2.06–1.96 (m, 1H), 1.77–1.73 (m, 2H); 13C NMR 
(126 MHz, CDCl3) δ 143.9, 142.2, 134.6, 134.5, 130.0, 129.9, 129.8, 127.8, 126.5, 124.6, 78.9, 71.4, 46.9, 
31.6, 21.7; LRMS (ES + APCI) m/z: 351.9 [M]+; HRMS (ESI-TOF) m/z: [M+H]+ calcd. for 
C17H1935ClNO3S 352.0774; found 352.0770. 
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(±)-2-(4-(1,3-Dioxalan-2-yl)phenyl)-1-tosylpyrrolidin-3-ol (19). Reaction of (E)-N-(4-(4-(1,3-dioxalan-
2-yl)phenyl)but-3-en-1-yl)-4-methylbenzenesulfonamide (200 mg, 0.54 mmol) and malonoyl peroxide 1 
(103 mg, 0.80 mmol) in HFIP (1.1 mL) according to General Procedure 3 followed by hydrolysis in 1 M 
NaOH:THF (5.3 mL, 1:1) gave the crude alcohol (1:9 cis:trans). Purification by silica gel flash column 
chromatography (hexane:EtOAc 1:1) gave the title compound 19 (115 mg, 0.30 mmol, 55%) as a white 
solid. m.p. 146–148 °C; IR (ATR)/cm–1: 3517, 3054, 2922, 2887, 2852, 1702; 1H NMR (400 MHz, CDCl3) 
δ 7.72 (d, J = 8.2 Hz, 2H), 7.43 (d, J = 8.2 Hz, 2H), 7.34 (d, J = 8.0 Hz, 2H), 7.28 (d, J = 8.0 Hz, 2H), 
5.79 (s, 1H), 4.66 (bs, 1H), 4.13–4.07 (m, 3H), 4.05–4.00 (m, 2H), 3.71–3.66 (m, 1H), 3.51 (dt, J = 9.9, 
6.9 Hz, 1H), 2.41 (s, 3H), 2.01–1.92 (m, 1H), 1.73–1.75 (m, 2H); 13C NMR (101 MHz, CDCl3) δ 143.7, 
141.1, 137.4, 134.7, 129.7, 127.9, 126.8, 126.4, 103.6, 78.9, 71.8, 65.4, 46.9, 31.4, 21.7; LRMS (ES + 
APCI) m/z: 390.0 [M+H]+; HRMS (ESI-TOF) m/z: [M+H]+ calcd. for C20H24NO5S 390.1375; found 
390.1370. 
(±)-1-Tosyl-2-(4-(trifluoromethyl)phenyl)pyrrolidine-3-ol (20). Reaction of (E)-4-methyl-N-(4-(4-trifluo-
romethyl)phenyl)but-3-en-1-yl)benzenesulfonamide (50 mg, 0.1 mmol) and malonoyl peroxide 1 (35 mg, 
0.3 mmol) in HFIP (0.6 mL) according to General Procedure 3 warming up to 50 °C, followed by hydrol-
ysis in 1 M NaOH:THF (2.6 mL, 1:1) gave the crude alcohol. Purification by silica gel flash column 
chromatography (hexane:EtOAc 4:6) gave the title compound 20 (10 mg, 0.03 mmol, 19%) as a white 
solid. m.p. 119–120 °C; IR (ATR)/cm–1: 3541, 2996, 2888; 1H NMR (500 MHz, CDCl3) δ 7.72 (d, J = 
8.0 Hz, 2H), 7.57 (d, J = 8.0 Hz, 2H), 7.46 (d, J = 8.0 Hz, 2H), 7.30 (d, J = 8.0 Hz, 2H), 4.69 (bs, 1H), 
4.15 (bs, 1H), 3.74–3.70 (m, 1H), 3.55–3.50 (m, 1H), 2.42 (s, 3H), 2.01–1.95 (m, 1H), 1.78–1.74 (m, 2H); 
13C NMR (126 MHz, CDCl3) δ 144.1, 144.0, 134.3, 130.0 (JC-F = 13.8 Hz), 129.8, 127.9, 126.8, 125.7 
(JC-F = 3.6 Hz), 124.2 (JC-F = 272.0 Hz), 78.9, 71.5, 47.0, 31.6, 21.7; LRMS (ES + APCI) m/z: 386.0 
[M+H]+; HRMS (ESI-TOF) m/z: [M+H]+ calcd. for C18H19F3NO3S 386.1038; found 386.1030. 
(±)-2,2-Diphenyl-1-tosylpyrrolidin-3-ol (21). Reaction of N-(4,4-diphenylbut-3-en-1-yl)-4-methylben-
zenesulfonamide (80 mg, 0.21 mmol) and malonoyl peroxide 1 (41 mg, 0.32 mmol) in HFIP (0.4 mL) 
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according to General Procedure 3 followed by hydrolysis in 1 M NaOH:THF (2.1 mL, 1:1) gave the crude 
alcohol. Purification by silica gel flash column chromatography (hexane:EtOAc 6:4) gave the title com-
pound 21 (68 mg, 0.17 mmol, 82%) as a white solid. m.p. 153–154 °C; IR (ATR)/cm–1: 3502, 3054, 2980, 
2954; 1H NMR (400 MHz, CDCl3) δ 7.49–7.47 (m, 2H), 7.43–7.34 (m, 3H), 7.30–7.25 (m, 3H), 7.20–
7.17 (m, 2H), 6.96 (d, J = 8.1 Hz, 2H), 6.86–6.83 (m, 2H), 4.79 (dd, J = 7.9, 6.0 Hz, 1H), 4.04 (ddd, J = 
9.4, 8.4, 3.9 Hz, 1H), 3.62 (ddd, J = 9.4, 8.4, 7.2 Hz, 1H), 2.33 (s, 3H), 2.17–2.10 (m, 1H), 1.77–1.67 (m, 
1H), 1.43 (bs, 1H); 13C NMR (101 MHz, CDCl3) δ 142.3, 139.0, 138.5, 138.2, 130.8, 130.0, 128.9, 127.93, 
127.89, 127.7, 126.6, 79.2, 77.1, 46.4, 30.6, 21.5 (1 carbon missing); LRMS (ES + APCI) m/z: 394.0 
[M+H]+; HRMS (ESI-TOF) m/z: [M+H]+ calcd. for C23H24NO3S 394.1477; found 394.1471. 
(±)-2-Phenyl-1-tosylpyrrolidin-3-ol (22). Malonoyl peroxide 1 (45 mg, 0.35 mmol) was added to a solu-
tion of (Z)-4-methyl-N-(4-(p-tolyl)but-3-en-1-yl)benzenesulfonamide35 (70 mg, 0.23 mmol) in HFIP (0.5 
mL) and mixture stirred at rt for 5 h. The solvent was removed by rotary evaporation and the resulting 
residue was directly treated with 1 M NaOH:THF (2 mL (1:1)). The solution was stirred at 60 °C for 18 
h, allowed to cool to rt and the aqueous phase was extracted with EtOAc (3 × 50 mL). The combined 
organics were washed with brine (100 mL) and dried over MgSO4. Removal of the solvent under reduced 
pressure afforded the crude pyrrolidine product (4:1 cis:trans). Purification by silica gel flash column 
chromatography (EtOAc:Hexane 4:6) gave the title compound 22 (37 mg, 0.11 mmol, 50 %), as a white 
solid. m.p. 114–116 °C; IR (ATR)/cm-1: 3452, 2974, 2872, 1325, 1156; 1H NMR (400 MHz, CDCl3) δ 
7.69–7.64 (m, 2H), 7.39–7.28 (m, 7H), 4.74 (d, J = 5.6 Hz, 1H), 4.25–4.15 (m, 1H), 3.80–3.70 (m, 1H), 
3.64 (ddd, J = 10.7, 7.7, 4.9 Hz, 1H), 2.43 (s, 3H), 1.89 (ddt, J = 16.3, 6.5, 4.9 Hz, 1H), 1.80–1.69 (m, 
1H), 1.09 (d, J = 4.9 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ 143.7, 136.5, 135.0, 129.8, 128.8, 128.7, 
128.3, 127.9, 127.7, 126.3, 73.7, 67.7, 47.2, 32.5, 21.7; LRMS (ES + APCI) m/z: 318.0 [M+H]+. 
2-(3-Bromo-4,4-diphenylbut-3-en-1-yl)isoindoline-1,3-dione. Bromine (0.3 mL, 5.7 mmol) was added 
dropwise to a solution of 2-(4,4-diphenylbut-3-en-1-yl)isoindoline-1,3-dione (1.0 g, 2.8 mmol) in 1,2-
DCE (5 mL) at room temperature. The resulting solution was stirred for 15 h before the solvent was 
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removed under reduced pressure. The residue was dissolved with a solution of KOH (0.6 g, 11.3 mmol) 
in MeOH (10 mL) and stirred for 30 min. The solids were then separated by filtration and filtrate was 
concentrated under reduced pressure affording the title compound (1.2 g, 2.7 mmol, 98%) as a cream solid 
that was used without further purification. m.p. 192–193°C; IR (ATR)/cm–1: 2942, 1699, 1123, 695; 1H 
NMR (400 MHz, CDCl3) δ 7.88–7.81 (m, 2H), 7.78–7.71 (m, 2H), 7.38–7.24 (m, 5H), 7.23–7.17 (m, 1H), 
7.16–7.09 (m, 2H), 7.01–6.95 (m, 2H), 4.02 (t, J = 6.3 Hz, 2H), 3.08 (t, J = 6.3 Hz, 2H); 13C NMR (101 
MHz, CDCl3) δ 168.0, 144.4, 142.9, 139.8, 133.9, 132.3, 129.0, 128.5, 128.6, 128.1, 127.4, 127.4, 123.3, 
122.9, 37.7, 37.0; LCMS (ES + APCI) m/z: 331.9, 434.0 [M+H]+; HRMS (ESI-TOF) m/z: [M+H]+ calcd. 
for C24H1979BrNO2 432.0599; found 432.0589. 
2-(3-(Diphenylmethylene)pent-4-en-1-yl)isoindoline-1,3-dione. To a solution of 2-(3-bromo-4,4-diphe-
nylbut-3-en-1-yl)isoindoline-1,3-dione (1.0 g, 2.3 mmol) in degassed EtOH (10 mL) was added potassium 
vinyltrifluoroborate (0.4 g, 2.8 mmol), and Pd(dppf)Cl2 (0.2 g, 0.2 mmol) under a N2 atmosphere. The 
resulting mixture was stirred at rt before the addition of Et3N (0.8 mL, 5.6 mmol). The mixture was then 
heated to 120 °C and stirring was continued for 48 h. The reaction was allowed to cool to room tempera-
ture and the solvent removed under reduced pressure. The resulting solid was dissolved in CH2Cl2 (20 
mL), washed with H2O (20 mL), dried over MgSO4, filtered and the solvent was removed by rotary evap-
oration. Purification by silica gel flash column chromatography (petroleum ether (40–60 °C):EtOAc 9:1) 
afforded the title compound (350 mg, 0.9 mmol, 40% (80% pure)) as a cream solid. m.p. 135–137°C; IR 
(ATR)/cm–1: 3024, 1696, 1399, 1104, 988; 1H NMR (400 MHz, CDCl3) δ 7.80 (dd, J = 5.5, 3.0 Hz, 2H), 
7.70 (dd, J = 5.5, 3.0 Hz, 2H), 7.37–7.14 (m, 8H), 7.09 (dd, J = 6.5, 3.1 Hz, 2H), 6.58 (dd, J = 17.5, 11.0 
Hz, 1H), 5.61 (d, J = 17.5 Hz, 1H), 5.19 (d, J = 11.0 Hz, 1H), 3.89 (t, J = 7.2 Hz, 2H), 2.82 (t, J = 7.2 
Hz, 2H); 13C NMR (101 MHz, CDCl3) δ 168.1, 144.4, 142.2, 141.9, 136.0, 133.7, 132.3, 130.2, 129.1, 
128.9, 128.5, 128.2, 127.9, 126.9, 123.1, 114.5, 37.5, 28.1; LCMS (ES + APCI) m/z: = 380.5 [M+H]+; 
HRMS (ESI-TOF) m/z: [M+H]+ calcd. for C26H22NO2 380.1651; found 380.1638. 
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2-(3-(Diphenylmethylene)-5-hydroxypentyl)isoindoline-1,3-dione. To a solution of 2-(3-(diphenyl-
methylene)pent-4-en-1-yl)isoindoline-1,3-dione (220 mg, 0.6 mmol) in anhydrous THF (2 mL) was added 
BH3 (1.0 M in THF, 0.9 mL, 0.9 mmol) under a N2 atmosphere. The resulting solution was stirred at rt for 
4 h. After this time a 2 M solution of NaOH (2 mL) was added followed by H2O2 (28% w/w, 2 mL) and 
the mixture was further stirred for 2 h. Upon completion, the reaction was quenched by the addition of a 
2 M solution of HCl (10 mL) and the organic layer was extracted with CH2Cl2 (2 × 10 mL). The combined 
organics were washed with a saturated solution of Na2S2O5 (2 × 10 mL), dried over MgSO4, filtered and 
the solvent was removed by rotary evaporation. Purification by silica gel flash column chromatography 
(petroleum ether (40–60 °C):EtOAc 1:1) afforded the title compound (80 mg, 0.2 mmol, 33%) as a cream 
solid. m.p. 137–139°C; IR (ATR)/cm–1: 3434, 2964, 1685, 1399, 1043; 1H NMR (400 MHz, CDCl3) δ 
7.79 (dd, J = 5.4, 3.2 Hz, 2H), 7.70 (dd, J = 5.4, 3.2 Hz, 2H), 7.31–7.24 (m, 2H), 7.21–7.07 (m, 4H), 
7.06–7.00 (m, 2H), 6.87–6.83 (m, 2H), 3.81 (t, J = 6.5 Hz, 2H), 3.75 (t, J = 6.7 Hz, 2H), 2.68 (t, J = 6.5 
Hz, 2H), 2.62 (t, J = 6.7 Hz, 2H), 1.77 (bs, 1H); 13C NMR (101 MHz, CDCl3) δ 168.1, 143.7, 142.6, 
142.1, 133.8, 132.4, 131.5, 129.0, 128.9, 128.2, 128.1, 126.5, 126.4, 123.1, 61.3, 36.4, 35.7, 30.6; LCMS 
(ES + APCI) m/z: = 398.3 [M+H]+; HRMS (ESI-TOF) m/z: [M+H]+ calcd. for C26H24NO3 398.1756; 
found 398.1755. 
N-(3-(Diphenylmethylene)-5-hydroxypentyl)-4-methylbenzenesulfonamide (28). To a solution of 2-(3-(di-
phenylmethylene)-5-hydroxypentyl)isoindoline-1,3-dione (120 mg, 0.3 mmol) in EtOH (2 mL) was 
added hydrazine monohydrate (30 μL, 0.6 mmol) according to General Procedure 2 to give 5-amino-3-
(diphenylmethylene)pentan-1-ol. 
To a solution of 5-amino-3-(diphenylmethylene)pentan-1-ol in CH2Cl2 (2.0 mL) was added Et3N (60 μL, 
0.3 mmol) followed by p-TsCl (58 mg, 0.3 mmol) and DMAP (11 mg, 0.09 mmol) according to General 
Procedure 2. Purification by silica gel flash column chromatography (cyclohexane:EtOAc 7:3) afforded 
the title compound 28 (67 mg, 0.2 mmol, 53%) as a colourless gum. IR (ATR)/cm–1: 2878, 1322, 1153, 
700; 1H NMR (600 MHz, CDCl3) δ 7.66 (d, J = 8.1 Hz, 2H), 7.29–7.23 (m, 6H), 7.21–7.17 (m, 2H), 7.16–
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7.12 (m, 2H), 7.10–7.06 (m, 2H), 4.96 (t, J = 5.9 Hz, 1H), 3.64 (t, J = 7.0 Hz, 2H), 2.98 (t, J = 7.0 Hz, 
2H), 2.43 (s, 3H), 2.42–2.38 (m, 4H), 1.75 (bs, 1H); 13C NMR (151 MHz, CDCl3) δ 143.6, 143.2, 142.4, 
137.0, 131.4, 129.6, 129.5, 128.9, 128.8, 128.4, 128.2, 127.0, 126.6, 126.6, 61.0, 41.7, 35.2, 32.0, 21.6; 
LCMS (ES + APCI) m/z: = 422.3 [M+H]+; HRMS (ESI-TOF) m/z: [M+H]+ calcd. for C25H28NO3S 
422.1790; found 422.1786. 
Oxidative heterocyclisation with probe compound (28). Reaction of N-(3-(diphenylmethylene)-5-hydrox-
ypentyl)-4-methylbenzenesulfonamide 28 (170 mg, 0.4 mmol) and malonoyl peroxide 1 (77 mg, 0.8 
mmol) in HFIP (1.0 mL) according to General Procedure 5 to give a crude material. The crude was dis-
solved in PhMe (1.0 mL) and MeOH (0.5 mL) before the addition of TMS-CHN2 (2 M in Et2O, 1.0 mL, 
2.02 mmol) according to General Procedure 5. Purification by silica gel flash column chromatography 
(cyclohexane:EtOAc 3:1) afforded the cyclised furan compound 29 (104 mg, 0.2 mmol, 46% over 2 steps) 
as a colourless gum and bicycle product (16 mg, 0.03 mmol, 7%) as a colourless gum. 
1-Methyl 1-(3-(2-((4-methylphenyl)sulfonamido)ethyl)-2,2-diphenyltetrahydrofuran-3-yl) cyclopropane-
1,1-dicarboxylate (29). IR (ATR)/cm–1: 2954, 1722, 1438, 1323; 1H NMR (600 MHz, CDCl3) δ 7.63 (t, J 
= 7.5 Hz, 4H), 7.54 (d, J = 7.5 Hz, 2H), 7.31–7.16 (m, 8H), 4.69 (bs, 1H), 4.12–4.02 (m, 2H), 3.76 (s, 
3H), 2.86–2.76 (m, 1H), 2.77–2.64 (m, 2H), 2.45 (s, 3H), 2.36–2.29 (m, 1H), 2.20 (ddd, J = 15.0, 8.0, 6.5 
Hz, 1H), 2.06 (dt, J = 15.0, 7.5 Hz, 1H), 1.61–1.55 (m, 1H), 1.49–1.45 (m, 1H), 1.41–1.35 (m, 1H), 1.20–
1.14 (m, 1H); 13C NMR (151MHz, CDCl3) δ (ppm) 170.0, 168.6, 143.1, 142.6, 142.0, 137.0, 129.5, 127.9, 
127.8, 127.2, 127.2, 127.0, 126.9, 126.1, 90.3, 88.7, 64.0, 52.6, 39.1, 35.9, 34.4, 28.8, 21.5, 16.7, 16.5; 
LCMS (ES + APCI) m/z: = 586.3 [M+Na]+; HRMS (ESI-TOF) m/z: [M+Na]+ calcd. for C31H33NNaO7S 
586.1875; found 586.1873. 
Methyl 1-(5-(2-((4-methylphenyl)sulphonamide)ethyl)-6,6-diphenyl-2,7,8-trioxabicyclo[3.2.1]octan-1-
yl)cyclopropane-1-carboxylate (31). IR (ATR)/cm–1: 2954, 1723, 1328, 1161, 1040; 1H NMR (600 MHz, 
CDCl3) δ 7.75 (d, J = 7.9 Hz, 2H), 7.41–7.37 (m, 2H), 7.32–7.21 (m, 8H), 5.14 (dd, J = 7.3, 3.2 Hz, 1H), 
3.85 (s, 3H), 3.75–3.67 (m, 1H), 3.58 (dd, J = 11.3, 6.8 Hz, 1H), 3.14–3.07 (m, 1H), 2.99 (dt, J = 8.6, 4.2 
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Hz, 1H), 2.45 (s, 3H), 2.00 (td, J = 12.9, 7.0 Hz, 1H), 1.92–1.87 (m, 1H), 1.82–1.74 (m, 1H), 1.54 (dd, J 
= 13.6, 3.8 Hz, 1H), 1.50–1.45 (m, 1H), 1.41–1.32 (m, 3H); 13C NMR (151 MHz, CDCl3) δ 171.7, 143.3, 
141.1, 139.8, 136.8, 129.7, 128.5, 127.8, 127.7, 127.7, 127.1, 118.1, 90.7, 86.1, 59.2, 52.5, 39.3, 35.1, 
29.3, 29.1, 21.5, 14.6, 13.4; LCMS (ES + APCI) m/z: = 586.3 [M+Na]+; HRMS (ESI-TOF) m/z: [M+Na]+ 
calcd. for C31H33NNaO7S 586.1875; found 586.1972. 
General Procedure 4: Mitsunobu reaction. A dry three-neck flask was charged with cinnamyl alcohol 
(1.0 equiv), PPh3 (1.1 equiv) and N-hydroxyphthalimide (1.1 equiv) in anhydrous THF (0.25 M). The 
solution was cooled to 0 °C and diethyl azodicarboxylate (2.2 M in PhMe, 1.1 equiv) was added dropwise. 
The mixture was warmed to rt and stirred for 2.5 h. The solvent was removed by rotary evaporation before 
purification by silica gel flash column chromatography with hexane:EtOAc mixtures afforded the target 
compound. 
2-(Cinnamyloxy)isoindoline-1,3-dione.36 Cinnamyl alcohol (2.2 g, 16.0 mmol), PPh3 (4.6 g, 17.6 mmol) 
and N-hydroxyphthalimide (2.9 g, 17.6 mmol) were dissolved in anhydrous THF (64 mL) before the 
dropwise addition of diethyl azodicarboxylate (2.2 M in PhMe, 8.0 mL, 17.6 mmol) according to the 
General Procedure 4. Purification by silica gel flash column chromatography (hexane:EtOAc 8:2) af-
forded the title compound (4.3 g, 15.4 mmol, 96%) as a white solid. m.p. 148–150 °C, Lit37 [116–118 °C]; 
IR (ATR)/cm–1: 3058, 3028, 2948, 1790; 1H NMR (500 MHz, CDCl3) δ 7.82–7.80 (m, 2H), 7.74–7.71 
(m, 2H), 7.39–7.37 (m, 2H), 7.32–7.29 (m, 2H), 7.27–7.24 (m, 1H), 6.67 (d, J = 15.9 Hz, 1H), 6.47 (dt, 
J = 15.9, 7.1 Hz, 1H), 4.87 (d, J = 7.1 Hz, 2H); 13C NMR (126 MHz, CDCl3) δ 164.0, 137.7, 136.0, 134.6, 
129.0, 128.8, 128.6, 127.1, 123.7, 122.2, 78.8; LRMS (ES + APCI) m/z: 297.0 [M+NH4]+. 
(E)-2-((3-(4-Chlorophenyl)allyl)oxy)isoindoline-1,3-dione. (E)-3-(4-Chlorophenyl)prop-2-en-1-ol (300 
mg, 1.8 mmol), PPh3 (513 mg, 2.0 mmol) and N-hydroxyphthalimide (320 mg, 2.0 mmol) were dissolved 
in anhydrous THF (7.0 mL) before the dropwise addition of diethyl azodicarboxylate (2.2 M in PhMe, 
0.9 mL, 1.96 mmol) according to General Procedure 4. Purification by silica gel flash column chroma-
tography (hexane:EtOAc 8:2) afforded the title compound (200 mg, 0.6 mmol, 35%) as a white solid. m.p. 
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138–140 °C; IR (ATR)/cm–1: 3050, 2948, 1788, 1742; 1H NMR (400 MHz, CDCl3) δ 7.83–7.81 (m, 2H), 
7.74–7.72 (m, 2H), 7.32–7.27 (m, 4H), 6.63 (d, J = 15.9 Hz, 1H), 6.44 (dt, J = 15.9, 7.0 Hz, 1H), 4.85 (d, 
J = 7.0, 2H); 13C NMR (101 MHz, CDCl3) δ 163.8, 136.0, 134.5, 134.3, 134.2, 128.9, 128.8, 128.1, 123.5, 
122.8, 78.4; LRMS (ES + APCI) m/z: 314.0 [M+H]+; HRMS (ESI-TOF) m/z: [M+H]+ calcd. for 
C17H1335ClNO3 314.0584; found 314.0583. 
N-(Cinnamyloxy)-4-methylbenzenesulfonamide (33).38 To a solution of 2-(cinnamyloxy)isoindoline-1,3-
dione (4.5 g, 16.1 mmol) in EtOH (62 mL) was added hydrazine monohydrate (1.6 mL, 33.8 mmol) 
according to General Procedure 2 to give O-cinnamylhydroxylamine. 
To a solution of crude O-cinnamylhydroxylamine (16.1 mmol) in CH2Cl2 (65 mL) was added Et3N (27 
mL, 19.3 mmol) followed by p-TsCl (3.4 g, 17.7 mmol) and DMAP (0.6 g, 4.8 mmol) according to Gen-
eral Procedure 2. Purification by silica gel flash column chromatography (hexane:EtOAc 8:2) afforded 
the title compound 33 (2.9 g, 9.6 mmol, 60%) as a white solid. m.p. 109–110 °C, Lit37 [103 °C]; IR 
(ATR)/cm–1: 3220, 3058, 3026, 2924, 2870; 1H NMR (500 MHz, CDCl3) δ 7.83 (d, J = 8.3 Hz, 2H), 7.38–
7.25 (m, 7H), 6.91 (bs, 1H), 6.63 (d, J = 15.9 Hz, 1H), 6.22 (dt, J = 15.9, 6.8 Hz, 1H), 4.61 (d, J = 6.8, 
2H), 2.44 (s, 3H); 13C NMR (126 MHz, CDCl3) δ 145.1, 136.3, 136.0, 133.8, 129.9, 128.77, 128.75, 128.4, 
126.9, 122.9, 78.1, 21.8; LRMS (ES + APCI) m/z: 321.0 [M+NH4]+. 
(E)-N-((3-(4-Chlorophenyl)allyl)oxy)-4-methylbenzenesulfonamide (35). To a solution of (E)-2-((3-(4-
chlorophenyl)allyl)oxy)isoindoline-1,3-dione (202 mg, 0.6 mmol) in EtOH (2.3 mL) was added hydrazine 
monohydrate (61 μL, 1.3 mmol) according to General Procedure 2 to give (E)-O-(3-(4-chlorophenyl)al-
lyl)hydroxylamine. 
To a solution of crude (E)-O-(3-(4-chlorophenyl)allyl)hydroxylamine(0.6 mmol) in CH2Cl2 (2.2 mL) was 
added Et3N (120 μL, 0.8 mmol) followed by p-TsCl (107 mg, 0.6 mmol) and DMAP (22 mg, 0.2 mmol) 
according to General Procedure 2. Purification by silica gel flash column chromatography (hexane:EtOAc 
8:2) afforded the title compound 35 (102 mg, 0.3 mmol, 54%) as a white solid. m.p. 116–118 °C; IR 
(ATR)/cm–1: 3216, 3064, 2922, 2852; 1H NMR (500 MHz, CDCl3) δ 7.80 (d,  J = 8.3 Hz, 2H), 7.31 (d, J 
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= 8.0 Hz, 2H), 7.27–7.25 (s, 4H), 7.04 (bs, 1H), 6.54 (d, J = 15.9 Hz, 1H), 6.17 (dt, J = 15.9, 6.7 Hz, 1H), 
4.57 (bd, J = 6.7 Hz, 2H), 2.41 (s, 3H); 13C NMR (126 MHz, CDCl3) δ 145.0, 134.7, 134.4, 133.9, 133.7, 
129.8, 128.8, 128.6, 127.9, 123.6, 77.6, 21.7; LRMS (ES + APCI) m/z: 355.0 [M+NH4]+; HRMS (ESI-TOF) 
m/z: [M+H]+ calcd. for C16H1735ClNO3S 338.0618; found 338.0616. 
General Procedure 5: Oxidative cyclisation for the synthesis of isoxazolidines. Malonoyl peroxide 1 
(1.5 equiv) was added to a solution of alkene 33 or 34 (1.0 equiv) in HFIP (0.5 M). The mixture was 
stirred at 40 °C for 18 h before removal of the solvent by rotary evaporation. The residue was dissolved 
in PhMe (0.2 M) and MeOH (0.5 M) and a solution of TMS-CHN2 in Et2O (2.0 equiv) was added drop-
wise. The resulting mixture was stirred at rt for 2 h before the solvents were evaporated under reduced 
pressure. Purification of the crude material by silica gel flash column chromatography with petroleum 
ether (40–60 °C):Et2O mixtures afforded the target compounds. 
(±)-1-(((-3-Phenyl-2-tosylisoxazolidin-4-yl)oxy)carbonyl)cyclopropane-1-carboxylic acid (37). To a so-
lution of N-(cinnamyloxy)-4-methylbenzenesulfonamide 33 (151 mg, 0.50 mmol) in HFIP (1.0 mL) was 
added malonoyl peroxide 1 (96 mg, 0.75 mmol) according to General Procedure 5 (without the TMS-
CHN2 methyl ester formation) to give crude isoxazolidine (1:10 cis:trans). Purification by silica gel flash 
column chromatography (EtOAc then EtOAc:AcOH 0.5%) afforded the title compound 37 (178 mg, 0.41 
mmol, 83%) as a white solid for characterisation and X-ray analysis purposes. m.p. 137–139 °C; IR 
(ATR)/cm–1: 3550, 2930, 2852,1716, 1660; 1H NMR (500 MHz, CDCl3) δ 12.19 (bs, 1H), 7.88 (d, J = 
8.3 Hz, 2H), 7.44–7.34 (m, 7H), 5.61 (ddd, J = 6.0, 3.1, 0.7 Hz, 1H), 5.54 (bs, 1H), 4.44 (dd, J = 9.6, 3.1 
Hz, 1H), 4.39 (dd, J = 9.6, 6.0 Hz, 1H), 2.47 (s, 3H), 2.18–2.14 (m, 1H), 2.06–2.03 (m, 1H), 1.99–1.93 
(m, 2H); 13C NMR (126 MHz, CDCl3) δ 176.3, 170.0, 145.5, 136.3, 133.7, 129.9, 129.2, 129.1, 128.7, 
126.5, 84.9, 74.6, 66.9, 25.6, 23.5, 23.2, 21.9; LRMS (ES + APCI) m/z: 432.0 [M+H]+; HRMS (ESI-TOF) 
m/z: [M−H]− calcd. for C21H20NO7S 430.0960; found 430.0954. 
(±)-1-Methyl 1-((3R,4S)-3-phenyl-2-tosylisoxazolidin-4-yl) cyclopropane-1,1-dicarboxylate (34). To a so-
lution of N-(cinnamyloxy)-4-methylbenzenesulfonamide 33 (185 mg, 0.43 mmol) in HFIP (0.9 mL) was 
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added malonoyl peroxide 1 (82 mg, 0.65 mmol) according to General Procedure 5 to give crude isoxazol-
idine (1:10 cis:trans) which was dissolved in PhMe (2.2 mL) and MeOH (0.9 mL) before the addition of 
TMS-CHN2 (2 M in Et2O, 0.43 mL, 0.86 mmol) according to General Procedure 5. Purification by silica 
gel flash column chromatography (petroleum ether (40–60 °C):EtOAc 6:4) afforded the title compound 
34 (154 mg, 0.35 mmol, 80% over two steps) as a colourless oil. IR (ATR)/cm–1: 3028, 3062, 2954, 1727; 
1H NMR (500 MHz, CDCl3) δ 7.89 (d, J = 8.3 Hz, 2H), 7.47 (d, J = 7.3 Hz, 2H), 7.38–7.35 (m, 4H), 7.31 
(t, J = 7.3 Hz, 1H), 5.52 (ddd, J = 6.1, 4.1, 1.7 Hz, 1H), 5.56 (bs, 1H), 4.38 (dd, J = 9.3, 6.1 Hz, 1H), 
4.34 (dd, J = 9.3, 4.1 Hz, 1H), 3.80 (s, 3H), 2.46 (s, 3H), 1.67–1.51 (m, 4H); 13C NMR (126 MHz, CDCl3) 
δ 169.9, 169.4, 145.2, 137.3, 133.9, 129.8, 129.2, 129.0, 128.3, 126.6, 83.8, 74.4, 67.0, 53.0, 27.9, 21.9, 
17.6, 17.5; LRMS (ES + APCI) m/z: 463.0 [M+NH4]+; HRMS (ESI-TOF) m/z: [M+H]+ calcd. for 
C22H24NO7S 446.1273; found 446.1266. 
(±)-1-((3R,4S)-3-(4-Chlorophenyl)-2-tosylisoxazolidin-4-yl) 1-methylcyclopropane-1,1-dicarboxylate 
(36). To a solution of (E)-N-((3-(4-chlorophenyl)allyl)oxy)-4-methylbenzenesulfonamide 35 (66 mg, 0.20 
mmol) in HFIP (0.4 mL) was added malonoyl peroxide 1 (38 mg, 0.29 mmol) according to General Pro-
cedure 5 to give crude isoxazolidine (1:7 cis:trans) which was dissolved in PhMe (1.0 mL) and MeOH 
(0.4 mL) before the addition of TMS-CHN2 (2 M in Et2O, 0.2 mL, 0.40 mmol) according to General 
Procedure 5. Purification by silica gel flash column chromatography (petroleum ether (40–60 °C):EtOAc 
6:4) afforded the title compound 36 (80 mg, 0.17 mmol, 85% over 2 steps) as a white solid. m.p. 110–112 
°C; IR (ATR)/cm–1: 3040, 2930, 2904, 1719, 1697; 1H NMR (500 MHz, CDCl3) δ 7.87 (d, J = 8.3 Hz, 
2H), 7.42 (d, J = 8.5 Hz, 2H), 7.36 (d, J = 8.3 Hz, 2H), 7.33 (d, J = 8.5 Hz, 2H), 5.47–5.45 (m, 1H), 5.41 
(bs, 1H), 4.35–4.34 (m, 2H), 3.79 (s, 3H), 2.46 (s, 3H), 1.66–1.52 (m, 4H); 13C NMR (126 MHz, CDCl3) 
δ 169.8, 169.5, 145.3, 135.8, 134.3, 133.6, 129.9, 129.2, 129.1, 128.0, 83.7, 74.2, 66.5, 53.0, 27.9, 21.9, 
17.6, 17.5; LRMS (ES + APCI) m/z: 497.0 [M+NH4]+; HRMS (ESI-TOF) m/z: [M+H]+ calcd. for 
C22H2335ClNO7S 480.0889; found 480.0879. 
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(±)-2-Phenyl-1-tosylpyrrolidin-3-one (38).39 (2R,3S)-2-Phenyl-1-tosylpyrrolidin-3-ol 9a (100 mg, 0.32 
mmol) was dissolved in degassed MeCN (1.6 mL). IBX (265 mg, 0.95 mmol) was added and the mixture 
was stirred at 80 °C for 18 h. The mixture was filtered through Celite® and the solvent removed under 
reduced pressure. Purification by silica gel flash column chromatography (hexane:EtOAc 4:6) afforded 
the title compound 38 (84 mg, 0.27 mmol, 85%) as a colourless oil. m.p. 124–126 °C, Lit40 [140–141 °C]; 
IR (ATR)/cm–1: 2950, 2924, 2855, 1753; 1H NMR (500 MHz, CDCl3) δ 7.57 (d, J = 8.2 Hz, 2H), 7.32–
7.27 (m, 7H), 4.59 (s, 1H), 3.94 (ddd, J = 10.6, 9.0, 5.6 Hz, 1H), 3.72 (dt, J = 10.7, 8.1 Hz, 1H), 2.63–
2.55 (m, 1H), 2.49–2.42 (m, 1H), 2.42 (s, 3H); 13C NMR (126 MHz, CDCl3) δ 208.3, 144.4, 135.6, 133.9, 
130.0, 128.8, 128.4, 127.8, 127.0, 67.3, 44.2, 35.9, 21.7; LRMS (ES + APCI) m/z: 316.1 [M+H]+. 
(±)-2-Phenyl-1-tosylpyrrolidin-3-ol (22).39 To a cooled (0 °C) solution of (±)-2-phenyl-1-tosylpyrrolidin-
3-one 38 (64 mg, 0.20 mmol) in THF (1 mL) was added a solution of DIBAL-H (1 M in THF, 0.3 mL, 
0.30 mmol). The mixture was allowed to warm to room temperature and stirred for 3 h, before quenching 
with a 2 M solution of HCl (5 mL) and diluted with EtOAc (5 mL). The organic layer was separated and 
further extracted with EtOAc (3 × 10 mL). The combined organics were washed with brine (50 mL), dried 
over MgSO4, filtered and the solvent was removed under reduced pressure affording the title compound 
22 (50 mg, 0.16 mmol, 78%) as a colourless oil as a diastereomeric mixture (6:1 cis:trans). 1H NMR (400 
MHz, CDCl3) δ 7.69–7.64 (m, 2H), 7.39–7.28 (m, 7H), 4.74 (d, J = 5.6 Hz, 1H), 4.25–4.15 (m, 1H), 3.80–
3.70 (m, 1H), 3.64 (ddd, J = 10.7, 7.7, 4.9 Hz, 1H), 2.43 (s, 3H), 1.89 (ddt, J = 16.3, 6.5, 4.9 Hz, 1H), 
1.80–1.69 (m, 1H), 1.09 (d, J = 4.9 Hz, 1H). 
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